implantable device for controlled release of low solubility drug

专利摘要:
implantable low solubility controlled release drug delivery device are implantable drug delivery devices that are deformable between a relatively rectified shape suitable for positioning and a retention shape suitable for retaining the device within the bladder or other body cavity. when in the body cavity, the devices release the drug from solid drug units housed in the devices. The devices are designed to house the solid drug units in a manner that exposes one or more sides of the solid drug units to the fluid at the in vivo positioning site. Methods for using the devices for drug administration and device creation are also provided.
公开号:BR112013019410A2
申请号:R112013019410
申请日:2012-02-06
公开日:2019-09-24
发明作者:Lee Heejin；Linh Ho Duc Hong；Sansone Matthew
申请人:Taris Biomedical Inc；
IPC主号:

专利说明:

"IMPLANTABLE DEVICE FOR CONTROLLED RELEASE OF LOW SOLUBILITY DRUG"
Related Order Cross Reference
This application claims the priority of Provisional Patent Application No. ² US 61 / 439,665, filed on February 4, 2011, which is incorporated by reference in this document.
Background
Systematic methods of drug delivery can produce undesirable side effects and can result in drug distribution and metabolism by physiological processes, which, after all, reduce the amount of drug to reach the desired site. A variety of devices and methods have been developed to deliver drug in a more focused manner, for example, in a localized or regional manner, which can indicate many of the problems associated with systematic drug delivery. Localized drug delivery to some tissue sites, however, has room for improvement, particularly in relation to extended drug delivery with minimally invasive devices and methods with minimal patient discomfort with the presence of the device itself.
For example, interstitial cystitis (HF) is a urological condition characterized by pain, frequency and high urinary urgency. This condition may also involve varying degrees of urinary incontinence and sexual dysfunction. HF and painful bladder syndrome include patients with urinary pain not attributable to other cases, such as infection or urinary stones and are estimated to affect approximately 3 to 8 million people in the US alone, the majority of whom are women. Berry, et al., J. Urol. 186 (2): 540 to 44 (2011). HF is a serious condition with unsatisfactory medical needs. Other therapies could also benefit from improved drug delivery intravesical devices, particularly where localized delivery of a drug to the bladder is preferred or necessary — such as when the side effects associated with systematic drug delivery are intolerable and / or when viability oral administration is very low.
There is a need for intravesical drug delivery that is small enough to avoid discomfort and unnecessary pain during and followed by device placement in patients, which can reduce the number of surgical or interventional procedures required for drug delivery and delivery during delivery. treatment period — for example, which provides controlled delivery over an extended period and which can carry an effective amount of drug for the extended period in a sufficiently small cargo volume. In bladder applications, the device must be retained in a desired manner in the bladder and not be excreted before the
2/49 drug can be at least substantially released, even when the drug needs to be delivered over a period of several days or weeks.
Currently, conventional bladder treatments include (1) delivery through an installation that needs to be repeated, (2) delivery through conventional devices that need to be refilled once implanted; (3) delivery via catheters, which provides a path for bacteria to migrate to the bladder and (4) systematic delivery, which increases the risk of side effects and reduced exposure to the drug at the target site. In general, better devices are needed for controlled drug delivery to the bladder. Desirably, the implantable device should be easy to deliver (and if necessary, remove from it) to the bladder with reduced pain or discomfort to the patient.
PCT Order Publications No. ^Q WO 2010/151893 and WO 2010/151896 by Taris Biomedical Inc. describe drug delivery devices that provide controlled drug delivery from a housing. The device can be freely floating in a patient's bladder, although it is fully and tolerably retained in the patient's bladder by localized release of the drug over an extended period.
It would be desirable, however, to provide new designs for intravesical delivery of drug devices and other implantable devices capable of delivering drugs at effective release rates for a range of different drugs, including those with relatively low aqueous solubility.
summary
In one aspect, drug delivery devices are provided so that they include a drug housing portion that provides at least one solid drug unit that includes a drug and at least one housing that encloses a first portion of the surface of the at least a solid drug unit and has at least one defined opening that exposes a second portion of the surface of at least one solid drug unit. Drug release from the device is controlled by erosion of the second exposed portion of the surface of at least one solid drug unit and the device is elastically deformable between a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity and a retention shape suitable for retaining the device within the body cavity. The rate of drug delivery from the drug delivery device can be directly proportional and limited by the total exposed surface area of the solid drug units. Drug delivery can be substantially zero in order over an extended period, such as from one day to one month.
In another aspect, implantable drug delivery devices are provided so that they comprise a drug housing portion that provides at least two solid drug units and at least one housing. The at least one
3/49 housing encloses a first portion of the surface of each solid drug unit and has at least two defined openings that expose a second portion of the surface of each solid drug unit. The drug delivery device is elastically deformable between a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity and a retention shape suitable for retaining the device within the body cavity. In certain embodiments, the at least one housing comprises at least three defined openings so that a third portion of the surface of at least one solid drug unit is exposed. In particular embodiments, the at least one housing comprises at least four defined openings so that a third portion of the surface of each solid drug unit is exposed.
In a further aspect, a drug delivery device is provided that is insertable into a patient's bladder and comprises a retaining frame comprising an elastic thread that has a wound shape; a plurality of solid drug tablets, each having a peripheral surface between opposite end faces; and a plurality of modular housing units attached to the retaining frame and securing the plurality of solid drug tablets, wherein each modular housing unit holds one of the solid drug tablets around its peripheral surface and has one or two openings that expose, respectively, one or both end faces of said drug tablet.
In another aspect, a drug delivery device is provided that is insertable into a patient's bladder and includes a housing that provides a flexible elongated monolithic structure that has a longitudinal geometric axis and a plurality of substantially oriented separate drug reservoir lumens and perpendicular to the longitudinal geometric axis; and a plurality of solid drug tablets arranged in the plurality of separate drug reservoir lumens.
In yet another aspect, methods are provided for locally administering a drug to a patient. The method may include providing a drug delivery device that provides two or more solid drug units secured in at least one housing that encloses a first portion of the surface of each solid drug unit and has at least one defined opening that exposes a second the portion of the surface of each solid drug unit, the device which is elastically deformable between a relatively rectified shape suitable for insertion through a patient's urethra and a suitable retention shape for retaining the drug delivery device within the patient's bladder; inserting the drug delivery device in a relatively rectified format through the patient's urethra and into the patient's bladder; allowing the fluid in the patient's bladder to come in contact with the second portion of the
4/49 each solid drug unit and dissolving drug from the second portion of the surface of each solid drug unit, in the fluid in contact with said second portion thereby releasing the drug into the bladder.
Brief Description of the Drawings
Figure 1 is a representation of one embodiment of a drug delivery device that has a monolithic drug housing in a retention format.
Figure 2 is a representation of a portion of one embodiment of a drug delivery device that has a monolithic housing that is maintained in a relatively rectified shape.
Figure 3 is a representation of a portion of a form of a drug delivery device that has a monolithic housing that is in a retention format.
Figure 4 is a representation of a modality of a monolithic housing that has a continuous structure with multiple lumens of drug reservoir, in which the device is maintained in a relatively rectified format.
Figure 5 is a cross-sectional view of an embodiment of a monolithic housing that has lumens of a cylindrical drug reservoir with two defined openings.
Figure 6 is a representation of a portion of an embodiment of a drug delivery device that is in a retention format.
Figure 7 is a top view representation of a portion of an embodiment of a drug delivery device that has a monolithic structure.
Figure 8 is a top view representation of a portion of one embodiment of a drug delivery device in which a portion of the housing approximately conforms to the shape of a series of drug reservoir lumens.
Figure 9 is a top view representation of a portion of one embodiment of a drug delivery device in which one side of the device has walls that conform to the shape of a series of drug reservoir lumens.
Figure 10 is a top view representation of a portion of an embodiment of a drug delivery device in which the drug reservoir lumens have circular walls.
Figure 11 is a cross-sectional view of an embodiment of a drug reservoir lumen that has walls of different thickness and two defined openings.
Figure 12 is a cross-sectional view of an embodiment of a drug reservoir lumen that has convex walls and two defined openings.
Figure 13 is a cross-sectional view of an embodiment of a drug reservoir lumen that has concave walls and two defined openings.
5/49
Figure 14 is a cross-sectional view of an embodiment of a drug reservoir lumen that has walls of different thickness and a defined opening.
Figure 15 is a cross-sectional view of an embodiment of a drug reservoir lumen that has convex walls and a defined opening.
Figure 16 is a cross-sectional view of an embodiment of a drug reservoir lumen that has concave walls and a defined opening.
Figure 17 is a cross-sectional view of an embodiment of a drug reservoir lumen that has concave walls and houses a solid drug unit with a diameter greater than the width of the housing.
Figure 18 is a cross-sectional view of an embodiment of a drug reservoir lumen that has concave walls and houses a solid drug unit with a diameter smaller than the width of the housing.
Figure 19 is a representation of a modality of a modular housing unit that has a drug reservoir lumen and a retaining frame lumen.
Figure 20 is a representation of a modality of a modular housing unit that shows the attachment of overlapping portions of the drug reservoir lumen walls.
Figure 21 is a representation of a modality of a modular housing unit that shows the fixation of the ends of the walls that form the drug reservoir lumen.
Figure 22 is a representation of a method for creating a modular housing unit.
Figure 23 is a representation of a modular housing unit that has two defined openings and a retaining frame lumen.
Figure 24 is a representation of an embodiment of a device that has modular housing units connected by a retaining frame.
Figure 25 is a representation of an embodiment of a device that has modular housing units connected by a retaining frame.
Figure 26 is a representation of an embodiment of a retaining frame.
Figure 27 is a representation of a side view of an embodiment of the retaining frame shown in Figure 26.
Figure 28 is a top view representation of an embodiment of the retaining frame shown in Figure 26.
Figure 29 is a representation of a side view of an embodiment of a retaining frame.
6/49
Figure 30 is a representation of the retaining frame of Figure 26 in a relatively rectified shape.
Figure 31 is a representation of a modality of a modular housing unit that has two lumens of retaining frame.
Figure 32 is a representation of a modality of a modular housing unit that has two lumens of retaining frame.
Figure 33 is a representation of a modality of a retaining frame in a relatively rectified shape to which a modular housing unit has been arranged.
Figure 34 is a representation of an embodiment of a device that has modular housing units connected by a retaining frame.
Figure 35 is a representation of a modality of a retaining frame in a relatively rectified shape to which a modular housing unit has been arranged.
Figure 36 is a representation of an embodiment of a device that has modular housing units connected by a retaining frame.
Figure 37 is a representation of an embodiment of a device that has modular housing units connected by a retaining frame and separated by spacers.
Figure 38 is a representation of an embodiment of a spacer with two retaining frame lumens.
Figure 39 is a representation of an embodiment of a spacer with a retaining frame lumen.
Figure 40 is a graphical representation of the amount of drug released from a series of test devices.
Figure 41 is a representation of the chromatograms collected during a test of several devices.
Figures 42a and 42b illustrate a tablet made of 100% mitomycin C (MMC) and a housing module that contains the tablet that was used in an in vitro release rate experiment.
Figure 43 is a graph showing cumulative MMC release in vitro over an extended period comparing device module designs that have 100% variant surface areas of MMC tablets exposed to a release medium.
Figure 44 is a graph showing the cumulative release of MMC in vitro over an extended period comparing device modules loaded with tablets of different MMC / excipient formulations.
Detailed Description
7/49
Implantable devices and methods for delivering a drug from a device positioned through a lumen into a patient's body cavity, such as the bladder, are provided herein. Advantageously, the present devices allow low solubility drugs to be released at therapeutically effective controlled rates over an extended period. Importantly, the devices provide sufficient direct contact between the solid drug units and with a biological fluid that wraps the device when positioned in vivo, when it is retained in a body cavity. In embodiments, drug delivery from the device is controlled by erosion of an exposed portion of the surface of a solid drug unit, so that the drug delivery rate from the drug delivery device can be directly proportional and limited by the area of delivery. total exposed surface of the solid drug units.
The devices may be elastically deformable between a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity and a suitable retention shape for retaining the device within the body cavity. When in retention format after placement in the bladder, for example, devices can resist excretion in response to urination forces or other forces. Since the devices are designed to be retained within a lumen or body cavity, they are able to overcome some of the deficiencies of conventional treatments, such as those related to the bladder. The devices described in this document can be inserted once and deliver drug for a desired period of time without frequent surgery or interventions. As a result, the devices can reduce the opportunity for infection and side effects, increase the amount of drug delivered locally or regionally to the bladder, or improve the patient's quality of life during the treatment process. After drug delivery, devices can be removed or bioerosible, at least in part, to avoid a recovery procedure.
The device can be loaded with at least one drug in the form of solid drug units, such as tablets, capsules or pellets. Providing one or more drugs in solid form to a patient is often advantageous. Solid drugs can provide a relatively large drug load volume to the total device volume and potentially accentuate drug stability during shipment, storage, prior use, or previous drug release. Solid drugs, however, can be solubilized in vivo in order to diffuse into a patient's tissues and the rate of that solubilization must be sufficient to provide a therapeutically effective amount of drug. One or both of these objectives, together with others, can be achieved when the devices described in this document are used to
8/49 deliver one or more drugs, particularly if the drugs have low aqueous solubility.
The devices and methods disclosed in the present document based on those described in Patent Application No. ^Q US 2007/0202151 (MIT 11824); ^Q Patent No US 2009/0149833 (MIT 12988); US Patent Application No. ^Q 2010/0003297 (MIT 12805); ^Q Patent No US 2010/0331770 (TB 101); Patent Application No. ^Q US 2010/0330149 (TB 102); US Patent Application No. ^Q 2010/0060309 (TB 108); ^Q Patent No US 2011/0202036 (TB 107); ^Q Patent No US 2011/0152839 (TB 112); ^Q Patent No US 2011/0218488 (TB 103); PCT / US11 / 46843, filed on August 5, 2011 (TB 113); Order No. ^Q 13 / 267,560, filed on October 6, 2011 (TB 116); Order No. ^Q US 13 / 267,469, filed on October 6, 2011 (TB 117); and Order No. ^Q US 13 / 347,513, filed on January 10, 2012 (TB 120), each of which is incorporated by reference in this document.
I. The Implantable Drug Delivery Device
Generally, implantable drug delivery devices include a drug housing portion that provides at least one solid drug unit that includes a drug and at least one housing that encloses a first surface portion of the at least one solid drug unit and which has at least one defined opening that exposes a second portion of the surface of at least one solid drug unit. Drug release from the device is controlled by erosion of the second exposed portion of the surface of at least one solid drug unit and the device is elastically deformable between a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity and a retention shape suitable for retaining the device within the body cavity. The rate of drug delivery from the drug delivery device can be directly proportional and limited by the total exposed surface area of the solid drug units. In such an embodiment, the drug release in vivo can be substantially of zero order over an extended period, such as from one day to one month.
In one embodiment, the drug housing portion can include at least two solid drug units and at least one housing. The at least one housing encloses a first portion of the surface of each solid drug unit. At least another portion of each of the solid drug units can be exposed. As used in this document with respect to at least two solid drug units, an “exposed” portion of a solid drug unit is one that, due to a defined opening in the housing, has the ability to come into direct contact with a fluid, including a biological fluid, in the lumen or body cavity after
9/49 of device placement. In one embodiment, the biological fluid is urine and the lumen or body cavity comprises the bladder.
In some embodiments, the at least one housing comprises at least two defined openings so that a second portion of the surface of each of the at least two solid drug units is exposed.
In some embodiments, the at least one housing comprises at least three defined openings so that a third portion of the surface of at least one of the at least two solid drug units is exposed.
In some embodiments, the at least one housing comprises at least four defined openings so that a third portion of each of the at least two drug units is exposed.
As used herein in connection with at least one housing, the term "defined opening" refers to any hole in the at least one housing that exposes a portion of the surface of a drug unit. Each defined opening can have any suitable shape, such as polygonal, circular, elliptical or non-circular. The size of each defined opening is limited only by the size of the device and the desired surface area of each solid drug unit that is exposed. Certain embodiments of the device expose a total surface area of at least one solid drug unit that remains substantially constant throughout or a substantial portion of the drug release period that can beneficially provide a relatively constant rate of drug release.
Generally, devices are elastically deformable between a relatively rectified shape suitable for insertion through a lumen (such as the urethra) into a patient's body cavity (such as the bladder) and a suitable retention shape to retain the device within the body cavity. In some embodiments, the material used to form the at least one housing is capable of forming the retaining shape without a retaining frame. In other embodiments, the material used to form the at least one housing is associated with a retaining frame.
The material used to form the at least one housing can be elastic or flexible to allow movement of the device between the relatively rectified shape and the retention shape. The material used to form the at least one housing can also be water-permeable, porous or both. A porous material can be drug permeable, depending on the particular drug used. The material used to form the at least one housing for one or more polymeric materials, biocompatible elastomeric materials or a combination thereof. In one embodiment, the at least one housing is made of silicone.
10/49
Generally, the at least one housing can have a monolithic or modular structure. Monolithic housings are continuous structures that house at least two solid drug units and may or may not include a retaining frame. As used in this document, a “continuous structure” is one in which the two or more drug closure portions of the housing are kept in contact with each other by the material or materials from which the housing is made, not by a frame retention. A retaining frame, however, can be included in devices that have a continuous, that is, monolithic structure. A "continuous structure," in certain embodiments, may include two or more different flexible materials that have been attached to each other to form the housing, or it may include a single material that is shaped to form the housing. Modular housings are typically formed of at least two separate housing units, each of which contains at least one solid drug unit. In some embodiments, the at least two separate modular housing units are connected by means of a retaining frame.
Monolithic housing
In certain embodiments, monolithic housings comprise a continuous material that defines one or more lumens of drug reservoir that are designed to enclose drug units. In other embodiments, monolithic housings comprise a continuous material that defines one or more drug reservoir lumens, which are designed to enclose the drug units and a retaining frame. The continuous material may or may not include one or more retaining frame lumens that house a retaining frame. In certain embodiments, the drug reservoir lumens and the retention frame lumen (s) are distinct from each other, although other configurations are possible. In particular embodiments, the retaining frame lumen (s) is (are) oriented parallel to the longitudinal geometric axis of the housing, although other alignments are possible.
In certain embodiments, housings comprising a flexible elongated monolithic structure having a longitudinal geometric axis and a plurality of separate drug reservoir lumens oriented parallel to the longitudinal geometric axis.
Figures 1, 2 and 3 show an embodiment of a drug delivery device 10 that has a monolithic drug housing. The housing, in this embodiment, includes an elongated silicone tube and comprises a plurality of solid drug units 12 (twenty-seven in this embodiment), each of which is revealed within separate portions 13 of at least one housing, each of which separate portion
11/49 has two defined openings 16a and 16b. The defined openings can be formed by cutting interfaces from the adjacent portions that house the solid drug units. The solid drug unit 12 can be a drug tablet or capsule. Adjacent portions 13, which may be called “drug reservoir lumens,” are, in this embodiment, segments of silicone tube that are connected together by means of at least one secondary tube 14. The lumen of the secondary tube is a lumen retaining frame. Within the lumen of the retaining frame, there is a retaining frame 15. In other embodiments, the housing is in a shape in addition to a tube.
The device shown in Figure 1 can flex between a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity (Figure 2) and a retention shape suitable for retaining the device within the body cavity (Figures 1 and 3). Figures 2 and 3 are approximate views of a portion of the device shown in Figure 1. As shown in Figures 1 and 3, in the retention format, open gaps 11 are provided between the separate portions 13 of the at least one housing. This allows the surfaces of the solid drug units in the gap to be exposed to the fluid at the in vivo positioning site. In this embodiment, drug dissolution and release from each drug unit 12 occurs from the two opposite sides of the drug unit. The area on the two opposite sides of the housing unit, in this mode, controls the drug release from each drug unit.
In embodiments that include a retaining frame, the retaining frame, when the device is in the retaining format, can have any orientation with reference to the monolithic housings or the modular housing units described in this document that are both inside, outside, above, as below the housing, or move in reference to the housing as the device moves through the lumen and into the body cavity in which it is positioned. For example, the device shown in Figure 1 includes a retaining frame 15 which is within the perimeter of the device housing. In other embodiments, the device includes a retaining frame that is below the housing (so that the retaining frame would not be visible in Figure 1).
A particular orientation between the housing and the retaining frame can be maintained by filling the retaining frame lumen with a filler material, such as a silicone adhesive, after the retaining frame is loaded into the retaining frame lumen. The filler material can cure or solidify to prevent movement of one portion in reference to the other. Other means of maintaining the orientation of the retaining frame with reference to the housing can also be used.
12/49
In the embodiment shown in Figure 1, the drug reservoir lumens 13 can have an internal diameter of about 1.3 to about 3.3 mm, such as about 1.5 to about 3.1 mm, a diameter about 1.7 to about 3.7 mm, such as about 1.9 to about 3.4 mm, and the housing can be about 12 to 21 cm long, such as about 14 to 16 cm.
In the embodiment shown in Figure 1 and other embodiments described herein, each drug reservoir lumen can hold one or more drug tablets or other solid drug units. In one embodiment, the device holds about 10 to 100 cylindrical drug tablets, such as mini tablets, among a number of distinct drug reservoir lumens. In certain embodiments, the mini tablets can each have a diameter of about 1.0 to about 3.3 mm, such as about 1.5 to about 3.1 mm and a length of about 1, 5 to about 4.7 mm, such as about 2.0 to about 4.5 mm.
In certain embodiments, the housings comprise a flexible elongated monolithic structure having a longitudinal geometric axis and a plurality of separate drug reservoir lumens oriented perpendicular to the longitudinal geometric axis.
Figures 4 and 5 show an embodiment of a monolithic housing 41 that has a single, continuous structure with multiple distinct drug reservoir lumens 42 and has at least one retaining frame lumen 43 in which a retaining frame 46 is arranged. Each drug reservoir lumen 42 has two defined openings, as shown in Figure 5 and is sized to hold at least one solid drug unit 44. The solid drug unit 44 can be a drug tablet or capsule. In other embodiments not shown, each drug reservoir lumen has a defined opening. The total shape of the housing 41 can be formed by a molding process or a combination of an extrusion process to form rods, strips or blades which can be subsequently cut. The drug reservoir lumens 42 can be created by a molding process or by a mechanical punching or drilling process. The housing can be formed of a flexible polymer, such as silicone.
Figure 5 is a cross-sectional view of the plane that cuts through one of the drug reservoir lumens 42 of the housing shown in Figure 4 along line 5-5. As shown in Figure 5, the monolithic housing 41 has two defined openings (45a, 45b) in its drug reservoir lumen 42 which exposes both flat ends of the solid drug unit 44. The retaining lumen 43, in this embodiment , is aligned parallel to the longitudinal geometric axis of the housing and perpendicular to the drug reservoir lumen 42.
13/49
Figure 6 is a perspective view of a portion of the device embodiment 41 shown in Figure 4 when the device is in its retaining shape, which is taken when the retaining frame 46 is arranged in the retaining frame lumen 43. The lumens of drug reservoir 42 and retaining frame 46 in the monolithic housing of this embodiment are oriented so that the lumens of drug reservoir 42 are outside the arch of the retaining frame 46. The housing in Figure 6 can be rotated 180 degrees around the retaining frame 46 to yield a configuration in which the drug reservoir lumens 42 are disposed within the arch of the retaining frame 46.
In device embodiments that include a retaining frame, the housings may terminate at the end of the retaining frame, the retaining frame being able to extend beyond the housings or a combination thereof.
In embodiments that include a retaining frame, the housing — which may or may not have a lumen of the retaining frame — and the retaining frame are associated with each other to form part of the drug delivery device. A variety of different associations are envisaged. For example, the longitudinal axis of the housing and the retaining frame can be at least partially aligned. In other words, the housing may extend over a portion or the entire length of the retaining frame, substantially parallel to or coincident with the retaining frame.
In other embodiments, the housing can be attached to only a portion of the retaining frame. The housing can have the first and second portions — such as the first and second end portions — and is attached to a portion or portions of the retaining frame. For example, the housing may include separate retaining frame lumens in the first and second end portions through which the retaining frame is threaded; or the housing may be deprived of lumens of the retaining frame so that the retaining frame is continuous and or intermittently attached to the housing by another suitable means, such as an adhesive.
In other embodiments, the portion of the housing enclosing the solid drug units may be continuously and or intermittently connected to a lumen of the retaining frame which may extend over a portion or the entire length of the housing. In some embodiments, the retention frame lumen may extend beyond the portion of the housing that encloses the solid drug units.
Figure 7 is a top view of the housing portion 41 shown in Figures 4 and 5. In the embodiment shown in Figure 7, the retaining frame lumen 43 and the housing portion that contains the drug reservoir lumens 42 that house to solid drug units 44, are connected along their entire lengths. Others
14/49 modalities, however, are provided for, such as those shown in Figures 8 to 10. Figures 8-10 depict possible alternative designs for the housing shown in Figure 7.
Figure 8 depicts a portion of an embodiment of a monolithic housing 81 in which the portion of the housing containing the drug reservoir lumens 82 has walls that approximately conform to the shape of the drug reservoir lumens 82 housing the drug units. solid 84. As a result, the portion of the housing containing the drug reservoir lumens 82 in Figure 12 is only intermittently connected to the retention frame lumen 83.
Figure 9 depicts a portion of an embodiment of a monolithic housing 91 in which the portion of the housing containing the drug reservoir lumens 92 has walls that conform to the shape of the drug reservoir lumens 92 on the side opposite the lumen retention frame 93. The retention frame lumen 93 is fixed along the entire length of the housing portion containing the drug reservoir lumens 92, which house the solid drug units 94.
Figure 10 depicts a portion of a monolithic housing 71 in which the circular walls that form the drug reservoir lumens 72 are connected to the retention frame lumen 73. In one embodiment of the monolithic housing in Figure 10, the walls that form a drug reservoir lumens 72 are connected to the walls that form the adjacent drug reservoir 72 lumens, which house the solid drug units 74. In another embodiment of the monolithic housing in Figure 10, the walls that form a drug reservoir lumen 72 are not connected to the walls that form the adjacent drug reservoir lumens. This embodiment can be formed by separately forming the drug reservoir lumens and fixing them to the retention frame lumen, and, if desired, fixing the adjacent lumen walls of the drug reservoir together. The drug reservoir lumens can be placed in the retention frame lumen so that they are adjacent to each other or can be separated from each other at any desired interval.
The housing designs shown in Figures 8 to 10 and other modalities described in this document can be used to reduce the total volume of the wall material that defines the drug reservoir lumens, thereby possibly increasing the accommodation flexibility, compressibility or both. In addition, the designs in Figures 7 to 10, in other embodiments, do not include a retaining frame lumen.
For all modalities described in this document, including those with modular housings, solid drug units can complete or
15/49 substantially the drug reservoir lumens. In one embodiment, any space in the drug reservoir lumen that does not contain the drug can be filled with a filling material. This can be done for the purpose of controlling the drug unit surface area exposed to biological fluid in vivo, and / or for the purpose of adding volume to the total device where the drug load is not required, but the total volume of device is necessary, for example, for purposes of allowing or enhancing the retention of the device in vivo. The filling material can be a polymeric material. The polymeric material can be placed in the drug reservoir lumen in a workable way and can be cured in it. Suitable polymeric materials can cure at room temperature or in response to an external stimulus, such as heat. The filler material can be a buoyancy enhancement material, such as a closed cell foam or component that contains and / or generates gas.
In modalities in which they exist, the gaps between the solid drug units can serve as reliefs that accommodate the deformation or movement of the device, while allowing the individual drug units to retain their solid form during storage and positioning. In this way, the drug delivery device can be relatively flexible or deformable rather than being loaded as a solid drug, as each drug unit can be allowed to move in reference to the adjacent drug units. Over the length of the device, the drug units may have the same composition or may vary in composition.
For all modalities described in this document, including those with modular housings, solid drug units can be retained in the drug reservoir lumens of the housings by friction coupling, adhesives, tongues, or other mechanical locking feature or a combination of themselves. For example, if the drug reservoir lumen has only one defined opening — that is, a closed end — then an adhesive can be applied to any of the walls of the drug reservoir lumen — such as the inner surface of the distal wall at the drug reservoir lumen — before inserting the solid drug unit into the drug reservoir lumen. As another example, if the drug reservoir lumen has two defined openings — that is, open at both ends — then the drug reservoir lumen can be formed in a way that increases the friction between the walls of the drug reservoir lumen. drug and the solid drug unit; the adhesive may or may not be used.
Generally, the walls that define the drug reservoir lumens can be of any shape capable of enclosing a solid drug unit. In certain embodiments, the walls that define the drug reservoir lumens
16/49 can be straight, concave or convex when viewed in cross section; and the thickness of the walls can vary.
Similar to Figure 5, Figures 11 to 16 are a cross-sectional view of a plane that cuts a drug reservoir lumen from a device similar to Figure 4. While Figure 5 depicts a cross-sectional view of the cylindrical reservoir lumen of drug 42 of Figure 4, Figures 11 to 16 depict cross-sectional views of several possible drug reservoir lumens that have different shapes and wall thicknesses. Each housing (110, 120, 130, 140, 150, 160) in Figures 11 to 16 includes a retaining frame lumen (113, 123, 133, 143, 153, 163) that is aligned perpendicular to the drug reservoir lumens (111, 121, 131, 141, 151, 161). In other embodiments not shown, the retaining frame lumen is aligned parallel to the drug reservoir lumen. The drug reservoir lumens (111, 121, 131, 141, 151, 161) in the housings (110, 120, 130, 140, 150, 160) can have two defined openings — that is, two opposite openings — as shown in Figures 11 to 13 or a defined opening — that is, a single opening — as shown in Figures 14 to 16.
In some embodiments, the walls that define the drug reservoir lumens can be of varying thickness. Housings with walls of different thicknesses can improve flexibility, compressibility of housing or both. Different wall thicknesses can also assist in securing a solid drug unit in the drug reservoir lumens. Examples of drug reservoir lumens with varying wall thicknesses are shown in cross section in Figures 11 and 14. One wall of the drug reservoir lumen (111, 141) is thicker than the other in these embodiments. Although these modalities depict the thinnest wall adjacent to the retention frame lumen (113, 143), other modalities of the housing can be configured so that the thinnest wall is on the side that is opposite the retention frame lumen (113, 143).
In some embodiments, the drug reservoir lumens in the devices described in this document may have a convex wall. The convex walls can assist in holding a solid drug unit, including a cylindrical solid drug unit, after it is inserted into the drug reservoir lumen. Examples of drug reservoir lumens with convex walls are shown in Figures 12 and 15. The convex walls (124, 154) can be made of an elastomer. Convex wall shapes can be produced when a low elastomer durometer blade is mechanically punctured. As used in this document, the term “low durometer” refers to a Shore hardness of less than 60A.
In some embodiments, the drug reservoir lumens in the devices described in this document may have a concave wall. The concave walls
17/49 can assist in securing a solid drug unit, including a spherical or ellipsoidal solid drug unit, in a drug reservoir lumen after it is inserted into the drug reservoir lumen. Figures 13 and 16 are cross-sectional views of possible drug reservoir lumens (131, 161) with concave walls (134, 164).
Figure 17 is a cross-sectional view of another housing 170 with a drug reservoir lumen 171 that has concave walls. Figure 17 shows that a drug reservoir lumen 171 having concave walls 172 can be used to hold a spherical drug tablet 173 that is slightly larger in diameter than the height of housing 170.
Figure 18 is a cross-sectional view of another housing 180 with a drug reservoir lumen 181 having concave walls 182. Figure 18 shows that a drug reservoir lumen 181 having concave walls 182 can be used to maintain a spherical drug tablet 183 which is slightly smaller in diameter than the height of housing 180. The housings (170, 180) shown in Figures 17 and 18 also include a retaining frame lumen (174, 184) which is aligned perpendicular to the lumens drug reservoir (171, 181) and parallel to the longitudinal geometric axes of the accommodation. In certain embodiments, an elastomeric wall material allows the insertion, in a drug reservoir lumen, of a spherical or ellipsoidal drug unit that has a larger diameter than the opening of the drug reservoir lumen. The drug reservoir lumen having a concave wall further facilitates the retention of such a drug unit.
If the diameter of a solid drug unit is slightly larger than that of a drug reservoir lumen and the wall defining the drug reservoir lumen is made of a low durometer or low rigidity material, thus making it easier, in certain embodiments, to insert the drug unit into the drug reservoir lumen if the lumen has a relatively thicker wall construction. Not wishing to be restricted by any particular theory, it is believed that this is due to the fact that the thicker wall can prevent the wall from being dragged, bent or collapsed during the process of inserting the solid drug unit into the reservoir lumen. drug. If a low durometer silicone is used as the building material for the housing and a thicker wall is needed for the drug reservoir lumen, then the silicone with a foam or porous structure can be used, in certain embodiments, to reduce the mass of the device. Even with a drug reservoir lumen that has a relatively thick wall, the total cross-sectional size must still be sized to fit the lumen of the
18/49 catheter, cystoscope or other positioning instrument. Regardless, the housing can be built with walls of any thickness.
Where possible, all the features described in this document can be applied to any housing of both monolithic and modular structures.
Modular housing
Modular housings are typically formed of at least two separate housing units, each unit housing at least one solid drug unit. The material from which each housing unit is formed defines at least one drug reservoir lumen capable of housing a solid drug unit. Drug reservoir lumens can have one or more defined openings. For example, the drug reservoir lumen may have opposite openings that expose correspondingly opposite end surfaces of the at least one solid drug unit housed therein.
In certain embodiments, at least two separate housing units in the modular housing are connected, directly or indirectly, by a retaining frame. In some embodiments, modular housing units can be placed on the retaining frame to form a “bracelet” design. The devices can have a housing unit or a plurality of housing units. The number of housing units can be limited only by the size of the retaining frame by which they are connected.
In some embodiments, one or more of the separate housing units includes a retaining frame lumen through which a shared retaining frame is extended. In certain embodiments, the retaining frame lumen and the drug reservoir lumen of each housing unit are arranged parallel to each other. In particular embodiments, the retaining frame lumen and the drug reservoir lumen of each housing unit are arranged perpendicular to each other. In additional embodiments, the retaining frame lumen and the drug reservoir lumen of each housing unit are arranged at an angle beyond 0 ^o (parallel) and 90 ° (perpendicular), such as 5, 10, 30, 45 , 60 or 85 °. In additional embodiments, the devices described in this document include two or more housing units with at least two of the following configurations: (1) the retaining frame lumen and the drug reservoir lumen are arranged substantially parallel to each other, (2) the retention frame lumen and drug reservoir lumen are arranged substantially perpendicular to each other and (3) the retention frame lumen and the drug reservoir lumen are arranged at an angle beyond 0 ^o (parallel ) and 90 ° (perpendicular).
19/49
Figure 19 is a perspective view of an embodiment of a drug unit housing 191, which contains a drug tablet 192. The walls of the drug unit housing define a drug reservoir lumen 193 and a frame lumen. retention 194. In this embodiment, the drug reservoir lumen 193 and the retention frame lumen 194 are oriented parallel to each other. The drug unit housing wall 195 that defines the drug reservoir lumen 193 encloses the cylindrical surface of the tablet and drug 192. In this embodiment, both ends of the housing unit 191 have a defined opening that exposes areas of opposite surfaces (the ends) of the solid drug tablet 192. In an embodiment not shown, the drug unit housing has only one defined opening.
Generally, the modular housing units described in this document can contain one or more solid drug units, such as tablets or capsules. The wall or closure material may, however, needlessly be water-permeable or drug-permeable. If the wall is drug-impermeable, then the drug's surface area in contact with urine or other body fluids affects the rate of drug release. Multiple housing units can be connected to a retaining frame to form the drug housing to achieve a selected drug release rate.
Generally, housing units can be formed integrally, such as by molding or extrusion, although separate construction and assembly of the wall lumen is possible. The retaining frame lumen wall, if present, may extend along the entire length of the drug reservoir lumen wall, so that the retaining frame lumen is the same length as the lumen of the drug reservoir. drug reservoir as shown in Figure 19, although one wall may be smaller than the other wall in other embodiments. In addition, the two walls can be fixed along the entire length of the device in the illustrated embodiment, although intermittent fixation can be employed.
Figures 20 to 22 depict how a housing unit (200, 210), such as that shown in Figure 19, can be formed and loaded with a solid drug unit, in certain embodiments. A drug reservoir lumen (201, 211) can be formed by rolling a flexible film or foil (for example, an elastic film or foil) and sealing the overlapping edges 202 (Figure 20) or adjacent edges 212 (Figure 21) in in conjunction with the use of any fastening method known in the art, including adhesives or chemical bonding or interlocking tabs or other mechanical connectors. The silicone adhesive or other medical grade adhesive can be used. Figure 22
20/49 shows that an assembly process for loading a drug tablet 204 into the drug reservoir lumen 201 of the housing unit 200 of Figure 20. In Figure 20, the drug reservoir lumen 201 is formed by securing one side of the film or blade to the overlapping portion 202 of the other. Each housing unit shown in Figures 20-22 includes a retaining frame lumen (203, 213) that is aligned parallel to the drug reservoir lumens (201, 211). In other embodiments, the housing units can be aligned perpendicular to the drug reservoir lumens.
Figure 23 is a perspective view of another embodiment of a housing unit that can be used in the modular housing described in this document. The housing unit 230 of Figure 23 contains a drug tablet 233. In this embodiment, the drug reservoir lumen 231 and the retaining frame lumen 232 are oriented perpendicular to each other. In this embodiment, both ends of the drug reservoir lumen have a defined opening that exposes a surface area of the tablet and drug 233. In another embodiment not shown, the drug reservoir lumen has only one defined opening. In the embodiment shown, the defined openings of the drug reservoir lumen 231 will be substantially perpendicular to the longitudinal geometric axis of the device.
Figure 24 shows a particular embodiment of device 241 in which several of the housing units 242 shown in Figure 23 are connected together by a retaining frame 243 that extends through the retaining frame lumens 244 of the housing units, which are enclosed a solid drug unit 246. The retaining frame 243 includes a circular closure 245 to improve the tolerance of the device. In the mode shown, the housing units are immovably attached to the retaining frame. In another embodiment not shown, the housing units can slide and / or rotate around the retaining frame.
Generally, the retention frame of the modular housings may include an enlarged portion at their ends to prevent the end of the retention frame from passing through the retention frame lumen of the at least terminal housing units. Typically, the enlarged portion should be of a size that exceeds the smallest diameter of the retaining lumen of the at least terminal housing units. The retaining frame itself can be shaped to form the enlarged portion or a closing material can be placed at the end of the retaining frame. Alternatively or in addition, the end portions of the retaining frame are preferably rounded and / or closed with soft material to facilitate patient tolerance of the inserted device.
In some embodiments, the retaining frame does not include an enlarged portion at its ends to prevent the end of the retaining frame from passing
21/49 through the retaining frame lumen of the at least terminal housing units. The extended portion is not necessary in certain embodiments, due to the fact that the housing units can be fixed immovably to the retaining frame, such as with friction or an adhesive. As used herein, “fixed immovably” means that the housing units are fixed so that they cannot (1) rotate around the retaining frame, (2) slide along the longitudinal geometric axis of the frame or (3) rotate around and slide along the retaining frame.
The housing units can be oriented with reference to the retaining frame so that, when in the retaining format, the housing is within the perimeter of the retaining frame, in addition to the perimeter of the retaining frame or a combination thereof.
In Figure 25, an embodiment of device 251 is shown in which the retaining frame 253 does not include an enlarged portion at its ends due to the fact that the housing units 252 enclosing a solid drug unit 256 are immovably attached to the frame retention frame 253. Retention frame 253 includes end closures 255 to improve device tolerance. Unlike the mode shown in Figure 24, each housing unit in the mode shown in Figure 25 is positioned outside the arch of the retaining frame 253. Alternatively, in a mode that is not shown, each housing unit in Figure 25 can be rotated by 180 degrees around the retaining frame and positioned within the arch of the retaining frame.
In some embodiments, the modular housing units can be uniformly oriented to any degree around the retaining frame. In other embodiments, one or more modular housing units can be oriented to varying degrees around the retaining frame.
Generally, the retaining frame can be of any shape that is capable of forming the retaining shape, thereby retaining the device in the lumen or body cavity to which it is positioned. Figure 26 is a perspective view of an embodiment of a retaining frame 261 that has two parallel circular parts 262 made of a single wire element, the circular parts being connected by a narrow curve 263 and having two end fasteners 264. This figure shows the retaining frame in its proper retaining shape to retain the device within the body cavity. Retention frame 261 can be formed of a superelastic alloy wire or strip, such as nitinol.
Figure 27 and Figure 28 provide a side view and a top view, respectively, of the device shown in Figure 26. Figure 29 is a side view of
22/49 an alternative embodiment of a retaining frame 291 in which the narrow curve of Figures 26 to 28 is placed with a loop 292, which connects the two circular parts 293, which ends with the end fasteners 294. Figure 30 depicts the retaining frame 261 of Figure 26, but in a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity, for example, through the patient's urethra into the bladder.
Generally, the housing units of the modular housings described in this document may have one or more lumens of retaining frame for housing the various designs of retaining frame. For example, as shown in the perspective view of Figure 31, a modular housing unit 311 can have two lumens of retaining frame 312a, 312b. In this particular embodiment, the two retaining frame lumens 312a, 312b are parallel to each other and to the drug reservoir lumen 313, which houses a solid drug unit 314. In the embodiment shown, the drug reservoir lumen 313 has two openings defined. In an embodiment not shown, the drug reservoir lumen has a defined opening.
Another embodiment of a modular housing unit is shown in Figure 32, which is a perspective view of a modular housing unit 321 that has two lumens of retaining frame 322a, 322b. In this embodiment, the two retaining frame lumens 322a, 322b are parallel to each other and perpendicular to the drug reservoir lumen 323, which houses a solid drug unit 324. In the embodiment shown, the modular housing unit has two defined openings . In an embodiment not shown, the modular housing unit has a defined opening.
The housing unit modalities shown in Figures 31 and 32 can be used with the retaining frame modalities shown in Figures 26 to 29. For example, Figure 33 shows a single housing unit of the modality shown in Figure 31, where each of the retaining frame lumens (312a, 312b) is threaded by one of the long segments 262 of the retaining frame 261 of Figure 30, which is in a relatively rectified shape suitable for insertion through a lumen into a body cavity of a patient. In this embodiment, the retaining frame is elastic and will return to the proper retaining shape to retain the device within the body cavity as shown in Figure 34 which depicts a mounted device 341, in which nine housing units 342 are threaded into the retaining frame 343 and the device is in its retention format.
Similarly, Figure 35 shows a single housing unit of the embodiment shown in Figure 32, in which each of the retaining frame lumens (322a, 322b) is threaded by one of the long segments 262 of the retaining frame of Figure 30 which is in a relatively rectified format suitable for insertion through
23/49 a lumen in a patient's body cavity. In one embodiment, the retaining frame is elastic and will return to the proper retaining shape to retain the device within the body cavity, as shown in Figure 36, which depicts an assembled device 361, in which nine housing units 362 are threaded into the retaining frame 363 and the device is in its retaining shape. Although these arrangements include nine housing units, the devices in this document may include a housing unit or the largest number of housing units that will fit into a particular retaining frame.
In certain embodiments, it may be desirable to maintain a selected space between adjacent accommodation units. In some embodiments, for example, spacers can be used to ensure that the defined openings of the housing units are not partially or completely interrupted by the adjacent housing units. Spacers can generally have one or more lumens that accommodate the passage of a retaining frame through the spacer. As with the housing units, the spacers may or may not be immovably attached to the retaining frame. Spacers can generally be made of silicone or other biocompatible material.
Figure 37 shows an embodiment of the drug delivery device 371 in which spacer elements 374 (i.e., spacers) are provided between housing units 372 which are connected via retaining frame 373. The spacer can be useful when, in certain embodiments, the curvature of the retaining frame is small. Figures 38 and 39 are seen in perspective of two possible designs for spacers, such as those shown in Figure 37. In Figure 38, spacer 381 has two separate parallel lumens 38, through each of which, one of the frame segments can be arranged. In Figure 39, spacer 391 has a single relatively larger and oval lumen 392, through which both segments of the retaining frame can be arranged. Spacers can be placed between alternating modular housing units or in any other range.
Although monolithic housings and modular housings have already been explained separately in this disclosure, the features described in this document, where possible, can be applied to both types of devices. In addition, hybrid devices that include housings that are partly monolithic and partly modular are also envisaged.
Any of the defined openings or ends of the housings, including the monolithic housing and the modular housing units, can be sealed if it is desired to close an opening. This sealing can be completed with a sealing substance or structure. The sealing structure can be formed of biocompatible material,
24/49 including a metal such as stainless steel, a polymer such as silicone, a ceramic or sapphire or adhesive, among others or combinations thereof. The sealing substance or structure can be biodegradable or bioerosible. In one embodiment, a medical grade silicone adhesive or other adhesive is loaded into the opening in a fluid or workable manner and then cure within the housing opening to seal it.
If a particular device has a monolithic or modular housing, the devices described in this document can be of a size that allows insertion into a lumen and a body cavity, such as the urethra and bladder, respectively.
The devices can be inserted into a patient using a cystoscope or catheter. Typically, a cystoscope for an adult human has an outside diameter of about 5 mm and a working channel that has an inside diameter of about 2.4 mm to about 2.6 mm. In embodiments, a cystoscope may have a working channel with a larger internal diameter, such as an internal diameter of 4 mm or more. In this way, the device can be relatively small in size. For example, when the device is elastically deformed to a relatively rectified shape, the device for an adult patient may have a total outside diameter that is less than about 2.6 mm, such as between about 2.0 mm and about 2.4 mm. For pediatric patients, the dimensions of the device are anticipated to be smaller, for example, proportional, for example, based on differences in anatomical size and / or differences in drug dosage between adult and pediatric patients. In addition to allowing insertion, the relatively small size of the device can also reduce patient discomfort and bladder trauma.
In one embodiment, the total configuration of the device promotes in vivo tolerance for most patients. In a particular embodiment, the device is configured for tolerance based on the characteristics of the bladder and design considerations described in Patent Application No. ^Q US 2011/0152839 (TB 112) which is incorporated by reference into this document.
Within the three-dimensional space occupied by the device in the retention format, the maximum dimension of the device in any direction is preferably less than 10 cm, the approximate diameter of the bladder when filled. In some embodiments, the maximum dimension of the device in any direction may be less than about 9 cm, such as about 8 cm, 7 cm, 6 cm, 5 cm, 4.5 cm, 4 cm, 3.5 cm , 3 cm, 2.5 or less. In particular embodiments, the maximum dimension of the device in any direction is less than about 7 cm, such as about 6 cm, 5 cm, 4.5 cm, 4 cm, 3.5 cm, 3 cm, 2 , 5 cm or less. In preferred embodiments, the maximum dimension of the device in any direction is less than about 6 cm, such as about 5 cm, 4.5 cm, 4 cm, 3.5 cm, 3 cm, 2.5 cm or less. More particularly, three-dimensional space
25/49 occupied by the device is defined by three perpendicular directions. Along one of these directions, the device has its maximum dimension and along the other two directions the device can have smaller dimensions. For example, the smaller dimensions in the other two directions may be less than about 4 cm, such as about 3.5 cm, 3 cm, 2.5 cm or less. In a preferred embodiment, the device has a dimension in at least one of these directions that is less than 3 cm.
In some embodiments, the device may have a different dimension in at least two of the three directions and, in some cases, in each of the three directions, so that the device has a non-uniform shape. Due to the non-uniform shape, the device may be able to achieve a reduced compression orientation in the empty bladder which is also non-uniform in shape. In other words, a particular orientation of the device in the empty bladder may allow the device to exert less contact pressure against the bladder wall, making the device more tolerable for the patient.
The overall shape of the device may allow the device to reorient within the bladder to reduce its engagement or contact with the bladder wall. For example, the total exterior shape of the device can be curved and all or a majority of the exterior or exposed surfaces of the device can be substantially rounded. The device may also be substantially devoid of sharp edges and its outer surfaces may be formed of a material that experiences reduced frictional engagement with the bladder wall. Such a configuration can allow the device to reposition itself within the empty bladder so that the device applies low contact pressures to the bladder wall. In other words, the device can slide or roll against the bladder wall in a low-energy position, representing a position in which the device experiences less compression.
An example of a device that generally meets these characteristics is shown in Figure 1. In particular, the illustrated device is generally flat in shape even though the device occupies three-dimensional space. Such a device may define a minor geometry axis, around which the device is substantially symmetrical and a major geometry axis that is substantially perpendicular to the minor geometry axis. The device can have a maximum dimension in the direction of the major geometric axis that does not exceed about 6 cm and, in particular embodiments, is less than about 5 cm, such as about 4.5 cm, about 4 cm, about 3.5 cm, about 3 cm or less. The device can have a maximum dimension in the direction of the smaller geometric axis that does not exceed about 4.5 cm and, in particular embodiments, is less than about 4 cm, such as about 3.5 cm, about 3 cm or less. The device is curved about substantially its entire outer perimeter in both a larger cross-sectional plane and a smaller cross-sectional plane. In other words, the format
The total exterior of the device is curved and the cross-sectional shape of the device is rounded. In this way, the device is substantially devoid of edges, except for edges at the two flat ends, which are completely protected inside the device when the device is on a plane. These characteristics allow the device to reorient itself in a reduced compression position when the bladder is empty.
The device can also be small enough in the retention format to allow intravesical mobility. In particular, the device, when positioned, may be small enough to move within the bladder, such as to move freely or unimpeded across the entire bladder under most bladder filling conditions, facilitating patient tolerance the device. The free movement of the device also facilitates uniform drug delivery across the entire bladder.
The device can also be configured to facilitate flotation, such as using low density building materials for the housing components and / or incorporating gas or gas generating materials in the housing, as described, for example, in the Order n ^Q US 13 / 267,560, filed on October 6, 2011 (TB 116), which is hereby incorporated by reference. In general, the device in the dry and drug loaded state can have a density in the range of about 0.5 g / ml to about 1.5 g / ml, such as between about 0.7 g / ml to about 1.3 g / ml. In some embodiments, the device in the dry, drug-loaded state has a density that is less than 1 g / ml.
The implantable drug delivery device can be made to be completely or partially bioerosible so that no explanation or recovery of the device is required following release of the drug formulation. In some embodiments, the device is partially bioerosible so that the device, through partial erosion, breaks into non-erosive parts small enough to be excreted from the bladder. As used herein, the term "bioerosible" means that the device or part of it, degrades in vivo by dissolution, enzymatic hydrolysis, erosion, reabsorption or combinations thereof. In one embodiment, this degradation occurs at a time that does not interfere with the kinetics intended for drug release from the device. For example, substantial erosion of the device may not occur until after the drug formulation is substantial and or completely released. In another embodiment, the device is erosive and the release of the drug formulation is controlled at least in part by the degradation or erosion characteristics of the erosive device body. The devices described in this document can be designed to conform to the characteristics of those described in Order No. ^Q US 13 / 267,469, filed on October 6, 2011 (TB 117) which is incorporated by reference in this document.
27/49
Biocompatible erosive materials useful in construction are known in the art. Examples of such suitable materials include synthetic polymers selected from poly (amides), poly (esters), poly (ester amides), poly (anhydrites), poly (orthoesters), polyphosphazenes, pseudo poly (amino acids), poly (glycerol- sebacato) (PGS), copolymers thereof and mixtures thereof. In a preferred embodiment, the resorbable synthetic polymers are selected from poly (lactic acids), poly (glycolic acids), poly (lactic-co-glycolic acids), poly (caprolactones) and mixtures thereof. Other curable bioreabsorbable elastomers include derivatives of poly (cap rol acton a) (PC), poly (ester amides) based on amino alcohol (PEA) and poly (octane-diol citrate) (POC). PC-based polymers may require additional cross-linking agents, such as lysine disocyanate or 2,2-bis (8-caprolactone-4-yl) propane to obtain elastomeric properties.
Alternatively, the implantable drug delivery device can be at least partially non-bioerosible. It can be formed of medical grade silicone tubing, as known in the art. Other examples of suitable non-resorbable materials include synthetic polymers selected from poly (esters), poly (acrylates), poly (methacrylates), poly (vinyl pyrolidones), poly (vinyl acetates), poly (urethanes), celluloses, cellulose, poly (siloxanes), poly (ethylene), poly (tetrafluoroethylene) and other fluorinated polymers, poly (siloxanes), their copolymers and combinations thereof. Following the release of the drug formulation, the device and / or the retaining frame can be removed substantially intact or in multiple pieces.
The drug delivery device can be sterilized before being inserted into a patient. In one embodiment, the device is sterilized using a suitable process such as gamma irradiation or ethylene oxide sterilization, although other sterilization processes can be used.
Holding the device in a body cavity
The devices described in this document are elastically deformable between a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity and a retention shape suitable for retaining the device within the body cavity. In certain embodiments, the drug delivery device can naturally assume the retention shape and can be deformed, both manually and with the aid of an external device, to the relatively rectified shape for insertion into the body. Once positioned, the device can return spontaneously and or naturally return to the initial retention format for retention on the body.
28/49
For example, the device shown in Figure 1 is depicted in a retention format suitable for retaining the device within a body cavity. In contrast, the device portion shown in Figure 2 is in a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity. Following positioning on the body, the device can assume the retention format to retain the drug delivery device in the body or lumen cavity.
For the purposes of this disclosure, the term "retention shape" Generally indicates any shape suitable for retaining the device at the intended implantation site, including, without limitation, the pretzel shape shown in Figure 1 that is suitable for retaining the device in bladder. Similarly, the term “relatively rectified shape” generally indicates any shape suitable for positioning the drug delivery device on the body, including, but not limited to, the linear or elongated shape shown in Figure 2, which is suitable for positioning the drug. device through the working channel of the catheter, cystoscope or other positioning instrument positioned in a lumen of the body, such as the urethra.
In some embodiments, drug delivery devices do not require a retaining frame to be elastically deformable between a relatively rectified shape and a retaining shape. In these embodiments, the material from which the housing is formed makes the device capable of being elastically deformed between the two shapes.
In other embodiments, the drug delivery devices include a retaining frame that is associated with the housing. The properties of the retaining frame make the device function like a spring, deforming in response to a compressive load, but returning spontaneously to its initial shape once the load is removed.
The housing may include one or more lumens of the retaining frame through which the portions of a retaining frame are threaded. In some embodiments, the housing does not include a lumen of the retaining frame and the retaining frame is attached to the housing by any other means, such as an adhesive.
In certain embodiments, the retaining frame, as well as the devices themselves, can naturally assume the retention shape, can be deformed to the relatively rectified shape and can return spontaneously to the retention shape through insertion into the body. The retention frame in the retention format can be formed for retention in a body cavity and the retention frame in the relatively rectified shape can be shaped for insertion into the body through the working channel of a positioning instrument such as a catheter or cystoscope . To achieve such a result, the retaining frame may have an elastic limit, modulus, and / or
29/49 constant spring selected to prevent the device from assuming the relatively lower profile shape once implanted. Such a configuration can limit or prevent accidental expulsion of the device from the body under expected forces. For example, the device may be retained in the bladder during urination or contraction of the detrusor muscle.
In a preferred embodiment, the device is elastically deformable between a relatively rectified shape suitable for insertion through a catheter or cystoscope that extends through a patient's urethra and a curved or coiled shape suitable to retain the device within the bladder (that is, to prevent their expulsion from the bladder during urination) following release of the device from the end of the catheter or cystoscope. In a particular configuration of this embodiment, the device has an elastic wire or strip that serves as the retaining frame and the elastic wire or strip acts as a spring to keep the device in a curved or coiled shape in the absence of a compressive load on the device and when the device is under compression of the bladder walls during urination or other contraction of the patient's detrusor muscle.
In certain embodiments, the retaining frame includes or consists of an elastic thread or an elastic strip. In one embodiment, the elastic yarn may comprise a biocompatible shaped memory material or a biodegradable shaped memory polymer, as known in the art. The elastic thread may also include a relatively low modulus elastomer that may be relatively less prone to irradiation or cause an ulcer inside the bladder or other implantation site and may be biodegradable so that the device does not need to be removed. Examples of low modulus elastomers include polyurethane, silicone, styrenic thermoplastic elastomer and poly (glycerol-sebacate) (PGS). The elastic thread can be coated with a biocompatible polymer, such as a coating formed from one or more of silicone, polyurethane, styrenic thermoplastic elastomer, Silitek, Tecoflex, C-flex and Percuflex.
For example, in the embodiment shown in Figures 1 to 3, the retaining frame is an elastic thread formed by a superelastic alloy, such as nitinol and surrounded by the wall of the retaining frame lumen 14, which forms a protective cap around the frame retention in this modality. The wall can be formed of a material polymer, such as silicone. In other embodiments, the retaining frame may be an elastic thread formed from a superelastic alloy, such as nitinol, which is covered in a polymer coating, such as a silicone layer and is attached to the housing. In some embodiments, the retaining frame may be an elastic strip, such as an elastic strip formed from a superelastic alloy.
30/49
In some embodiments, the retaining frame lumen may include the retaining frame and a filler material, such as a silicone adhesive, such as MED3-4213 by Nusil Technology LLC, although other filler materials may be used. The filling material is optional and can be omitted; however, their inclusion can fill the void in the lumen of the retainer frame around the retainer frame and can reduce the tendency of the drug reservoir lumen to stretch along, or twist or rotate around the retainer frame, while holding the drug reservoir lumen in a selected orientation with reference to the retaining frame.
A retaining frame that takes on a pretzel shape, as in Figure 1, can be resistant to compressive forces. The pretzel shape essentially comprises two subcircles, each of which has its own smaller arc and shares a larger common arc. First, when the pretzel shape is compressed, the larger arc absorbs most of the compressive force and begins to deform, but with continuous compression, the smaller arcs overlap and subsequently, all three of the arcs resist compressive force. The compressive strength of the device as a whole increases as the two sub-circles overlap, preventing collapse and urination of the device as the bladder contracts during urination.
In modalities in which the retaining frame (or the housing itself in modes without a retaining frame) comprises a formatted memory material, the material used to form the frame can “memorize” and spontaneously assume the retention shape with the application heat to the device, such as when exposed to body temperatures upon entry into the bladder.
A high modulus material can be used for the retaining frame in some embodiments or, in other embodiments, a low modulus material. When a low modulus material is used, the retaining frame can have a diameter and / or shape that provides a spring constant without which the frame can deform significantly under the forces of urination. For example, the retaining frame may include one or more windings, coils, coils or combinations thereof, specifically designed to achieve a desirable spring constant, such as a spring constant in the range of approximately 3 N / m to approximately 60 N / m or more particularly, in the range of approximately 3.6 N / m to approximately 3.8 N / m. Such a spring constant can be achieved by one or more of the following techniques: increasing the diameter of the elastic yarn used to form the frame, increasing the curvature of one or more windings of the elastic yarn and adding additional windings to the elastic yarn. The windings, coils or spirals of the frame can have various configurations. For example, the frame may be in a corrugated configuration comprising one or more
31/49 loops, waves or subcircles. The ends of the elastic thread can be adapted to prevent scarring and tissue irritation, such as being smooth, blunt, directed inward, joined or a combination thereof.
The retaining frame may have a two-dimensional structure that is confined to a plane, a three-dimensional structure, such as a structure that occupies the interior of a spheroid or some combination thereof. The frames may comprise one or more loops, waves or subcircles, connected in a linear or radial manner, rotating in the same or alternating directions and which overlap or not. The frames can comprise one or more circles or ovals arranged in a two-dimensional configuration or a three-dimensional configuration, the closed or open circles or ovals having the same different sizes or sizes, overlapping or not, and joined at one or more points of connection. The retaining frame portion can also be a three-dimensional structure that is shaped to occupy or wrap around a spheroid-shaped space, such as a spherical space, a space that has a proportional spheroid shape, or a space that has a flat spheroid shape. The retaining frame portions can be shaped to occupy or wrap around a spherical space. The retaining frame portion can generally take the form of two crossed circles that are on different planes, two crossed circles that are on different planes with wavy ends inward, three crossed circles that are on different planes or a spherical spiral. In each of these examples, the retaining frame portion can be stretched to the linear shape for positioning using a positioning instrument. The retaining frame portion can wrap around or through the spherical or other spheroid-shaped space in a variety of other ways. One or both of the retaining frame and the retaining frame lumen may be omitted, in the event that the housing itself may assume or be deformed into any retaining shape described in this document. Examples of alternative configurations are described in the U.S. Patent Applications incorporated by reference in this document.
II. Drug Release
The drug from the solid drug units in the devices described herein can be released over an extended period. The rate of drug release from the drug reservoir portion is generally controlled by the design of the combination of device components that includes, but is not limited to, the materials, dimensions, exposed surface area of the solid drug units and openings the housing, as well as the formulation of a particular drug and the total drug load mass, among others. In some embodiments, drug delivery is controlled by dissolution, diffusion, or a combination thereof.
32/49
In certain embodiments, the housings are configured to expose a constant surface area of the solid units in the defined opening as the solid drug units are dissolved in the exposed surface area. The use of the term “accommodation” throughout the specification includes both monolithic and modular accommodation, unless otherwise noted. By increasing or decreasing the size of the openings defined in the housings, the rate of drug release can be controlled in these modalities. In one embodiment of the device designs described in this document, the erosion of the drug tablets on one or more exposed surfaces stipulates the rate of drug release.
In some embodiments, the housings can be configured to allow the segregation of two or more different drugs, or two or more different formulations of the same drug, in different reservoirs. These modalities can be combined and varied to achieve a desired combination therapy and / or release profile.
In some embodiments, the start of delivery of two doses in different reservoirs can be in stages, configuring the device accordingly. The device can release some drug relatively quickly after implantation while another drug can experience an induction time before starting to release.
An example of a drug delivery device is shown in Figure 1. As shown, device 10 includes several solid drug units 12 which are housed in separate tube portions 13 separated by intervals. The ends of the tube segments have defined openings (6a, 6b) that expose surface areas of the solid drug units. In one embodiment, when the device is positioned in the bladder, water or urine comes into contact with the drug units in the surface areas. Optionally, the device can be configured so that water or urine still permeates through the wall of the pipe segments, through one or more openings in the side wall of the pipe segments or through passage pores formed through a pipe segment porous. The material from which the tube is made can still be drug-permeable. Water or urine in contact with the solid drug unit causes the drug to be solubilized. The solubilized drug is diffused, in this modality, from the device at a controlled rate. The rate of drug dissolution can limit or control the rate at which drug is dispensed from the device. The rate of dissolution and, consequently, diffusion, can be adjusted by increasing or decreasing the size of the defined openings, using a porous material to form the housing, using a water-permeable material to form the housing, with the use of a drug-permeable material to form the housing or a combination thereof.
33/49
In addition to adjusting the sizes of the defined openings, the defined openings of the housings, in some modalities, can be positioned to facilitate the release of drug in a particular portion of a body cavity, such as the bladder. For example, the defined openings of the housings can be positioned inside the perimeter of the device, outside the perimeter of the device, or on a top or bottom plane of the device. An opening positioned on the inner perimeter or in the upper or lower plane of the device may be less likely to be positioned directly adjacent to a portion of the implantation site, such as the bladder wall, delivering a relatively greater amount of drug to a particular area of the implant. urothelium. Accordingly, such an interior perimeter placement of openings can be advantageous when uniform administration for the entire urothelium is desired.
The rate of drug release can also be controlled, at least in part, through the composition of the solid drug formulation and / or the use of coating substances on one or more surfaces of the solid drug units.
Solid drug units can be coated with one or more suitable bioerosible materials: to delay the start of drug release and dissolution; to protect the drug from destructive exposure to oxygen or moisture during tablet handling, device assembly and storage; to lubricate solid drug units to facilitate device loading; or a combination of them. Coating materials suitable for these purposes are known in the art.
Similarly, solid drug units can be mixed / formulated with one or more suitable excipient materials: to change (for example, delay or increase) the rate of drug release (for example, disintegrating agents); to protect the drug from destructive exposure to oxygen or moisture during tablet handling, device assembly and storage; to lubricate solid drug units to facilitate device loading; to facilitate the production of tablets (for example, binders) or a combination thereof.
The rate of drug release can also be controlled, at least in part, through the composition of the drug formulation. In some embodiments, the solid form of the drug does not include a matrix material, as inclusion of a matrix material (that is, dispersion of the drug in a non-degradable or degradable matrix material) can reduce loading efficiency and prevent and / or unnecessarily complicate drug release. When preventing the release of drug is desirable, however, other modalities may include a matrix material in the drug formulation.
Materials other than solid drug units can also be added to the housings, specifically the drug reservoir lumens, to change the
34/49 drug release. In one embodiment, any space in the drug reservoir lumen that does not contain the drug can be filled with a filling material. This can be done for the purpose of controlling the drug unit surface area exposed to biological fluid in vivo and / or for the purpose of adding volume to the total device where the drug load is not required, but the device volume total is necessary, for example, for the purposes of enabling or improving the retention of the device in vivo. The control of the drug unit surface area exposed to biological fluid in vivo allows the diffusion rate to be adjusted in certain modalities.
III. Drug Formulation and Solid Drug Tablets
Generally, a drug formulation is formed in solid drug units that are loaded into the housing of the devices. Each of the solid drug units is a discrete, solid object that substantially retains a selectively transmitted shape (under the conditions of pressure and temperature to which the delivery device will normally be exposed during assembly, storage and handling prior to implantation). Drug units can be in the form of tablets, capsules, pills or granules, although other configurations are possible.
Solid drug units can be formed using a scalable and stable manufacturing process. Particularly, the drug tablets are sized and shaped for loading into and efficiently storing the tablets in a housing of a drug delivery device that can be positioned in the bladder or other cavity, lumen or tissue site in a patient in one way. minimally invasive.
The solid drug units can be tapes through a direct compression tablet production process, a molding process or other processes known in the pharmaceutical art. Suitable drug tablet forming methods are described in Order Publication No. ² US 2010/0330149 (TB 102), which is hereby incorporated by reference. The drug formulation can also be loaded into the device housings in an executable form and can heal in them. For example, in the modalities in which the drug formulation is configured to be fused and solidified, the drug formulation can be fused, injected into the housing of the devices in the fused form and then solidified. The drug formulation can also be extruded with the device housings, can cure within the housings, and subsequently can be cut in separate positions along the length of the housing to form segments with the exposed drug surface area.
35/49
The solid drug unit includes a drug formulation that includes a drug content and can include an excipient content. In a preferred embodiment, the drug content includes one or more drugs or active pharmaceutical ingredients (API), while the excipient content includes one or more pharmaceutically acceptable excipients. The drug formulation can include essentially any diagnostic, therapeutic or prophylactic agent, such as one that can be useful to deliver locally to a body cavity or lumen or regionally around the body cavity or lumen. The drug formulation can consist of API only or one or more excipients can be included. As used herein, the term "drug" with reference to any specific drug described in this document includes its alternative forms, such as salt forms, free acid forms, free base forms and hydrates. The term "excipient" is known in the art and representative examples of excipients useful in the drug units present may include ingredients such as binders, lubricants, glidants, disintegrators, colors, fillers, thinners, coatings or preservatives, as well as other non-active ingredients for facilitate the manufacture, stability, dispersibility, wettability and / or kinetics of drug release or administration of the drug unit. The drug can be a small molecule, a macromolecule, a biological or a metabolite, among other forms / types of active ingredients.
In order to maximize the amount of drug that can be stored in and released from a given drug delivery device of a selected (small) size, the drug unit preferably comprises a high weight fraction of drug or API, with a low or reduced weight fraction of excipients as required for drug unit fabrication and device assembly and usage considerations. For the purposes of this disclosure, terms such as "weight fraction", "weight percentage" and "percentage by weight" with reference to the drug or API, refer to the drug or API in the form used, such as in the form of salt, free acid form, free base form or hydrate form. For example, a solid drug unit that has 90% by weight of a drug in salt form may include less than 90% by weight of that drug in the form of free base.
In one embodiment, the solid drug unit is greater than 50%, by weight, of drug. In another embodiment, 75% or more of the weight of the solid drug unit is drug, with the remainder of the weight comprising excipients, such as lubricants and binders that facilitate the creation of the solid drug unit. For the purposes of this disclosure, the term "high weight fraction" with reference to the drug or API means that excipients constitute less than 25% by weight, preferably less than 20% by weight, more preferably less than 15%, in weight, and even more preferably
36/49 less than 10%, by weight, of the solid drug unit. In some cases, the drug content comprises approximately 75% or more of the weight of the solid drug unit. More particularly, the drug content can comprise approximately 80% or more of the weight of the drug tablet. For example, the drug content can comprise between approximately 85% and approximately 99.9% of the weight of the solid drug unit. In some embodiments, the excipient content can be omitted altogether.
In one embodiment, the drug and excipients are selected and the solid drug unit formulated to be water-soluble, so that the solid drug units can be solubilized when the device is located inside the bladder, to release the solubilized drug.
The individual solid drug units can have essentially any selected dimension and shape that fits within the devices described in this document. In one embodiment, the solid drug units are sized and shaped so that the drug reservoir lumens in the housings are substantially filled by a selected number of solid drug units. Each solid drug unit may have a cross-sectional shape that substantially corresponds to a cross-sectional shape of the drug reservoir lumen of a particular housing. For example, drug units may be substantially cylindrical in shape for positioning in a substantially cylindrical drug reservoir lumen. Once loaded, the solid drug units may, in some embodiments, substantially fill the drug reservoir lumens, forming the drug housing portion.
In one embodiment, the solid drug units are shaped to line up in a row when the device is in its positioning configuration. For example, each solid drug unit can have a cross-sectional shape that corresponds to the cross-sectional shape of the drug reservoir lumens in the housing, and each solid drug unit can have end face shapes that correspond to the end faces of adjacent solid drug units. The interstices or cracks between the solid drug units can accommodate the deformation or movement of the device, such as during positioning, while allowing the individual drug units to retain their solid shape. Therefore, the drug delivery device can be relatively flexible or deformable despite being loaded with a solid drug, as each drug unit can be allowed to move with reference to the adjacent drug units.
In modalities in which solid drug units are designed for insertion or implantation into a lumen or cavity in the body, such as the bladder, by means of a drug delivery device, drug units can be
37/49 “mini-blocks” that are sized and shaped properly for insertion through a natural body lumen, such as the urethra. For the purpose of this disclosure, the term "mini tablet" generally indicates a solid drug unit that is substantially cylindrical in shape, having end faces and a side face that is substantially cylindrical. The mini tablet has a diameter that extends along the end face, in the range of approximately 1.0 to approximately 3.2 mm, such as between approximately 1.5 and approximately 3.1 mm. The mini tablet has a length that extends along the side face, in the range of approximately 1.7 mm to approximately 4.8 mm, such as between approximately 2.0 mm and approximately 4.5 mm. The tablet's friability can be less than approximately 2%. The modalities of solid drug units and systems and methods of creating them are further described below with reference to U.S. Patent Applications incorporated by reference herein.
In one embodiment, the drug formulation is in a solid form. In another embodiment, the drug formulation is in a semi-solid form, such as a highly viscous suspension or emulsion; a gel or a paste. As used herein, the solid form includes semi-solid forms unless otherwise indicated.
The drug can be a low solubility drug. As used herein, the term "low solubility" refers to a drug having a solubility from about 0.01 mg / ml to about 10 mg / ml of water at 37 ^Q C. In other embodiments, the drug is a high solubility drug. As used herein, the term "high solubility" refers to a drug that has a solubility greater than about 10 mg / ml of water in 37 ^Q C.
In one embodiment, the drug delivery device is used to treat urinary tract cancer, such as bladder cancer and prostate cancer. Drugs that can be used include antiproliferative agents, cytotoxic agents, chemotherapeutic agents or combinations thereof. Representative examples of drugs that may be suitable for the treatment of urinary tract cancer include the Bacillus Calmette Guerin (BCG) vaccine, docetaxel, cisplatin, doxorubicin, valrubicin, gemcitabine, cell wall complex and mycobacterial DNA (MCC), methotrexate , vinblastine, thiotepa, mitomycin (e.g., mitomycin C), fluorouracil, leuprolide, dietilstylbestrol, estramustine, megestrol acetate, cyproterone, flutamide, selective estrogen receptor modulators (ie, a SERM, such as tamoxifen), botulinum toxins and cyclophosphamide. The drug can comprise a monoclonal antibody, a TNF inhibitor, an anti-leukin or the like. The drug can still be an immunomodulator, such as a TLR agonist, including imiquimod or another TLR7 agonist. The drug can still be a kinase inhibitor, such as a tyrosine kinase inhibitor (FGFR3) -selective factor 3 receptor selective
38/49 fibroblast growth, a phosphatidylinositol-3-kinase inhibitor (PI3K) or a mitogen activated protein kinase inhibitor (MAPK), among others or combinations thereof. Other examples include celecoxib, erlotinib, gefitinib, paclitaxel, polyphenon E, valrubicin, neocarzinostatin, apaziquone, Belinostat, Ingenol mebutate, Urocidin (MCC), Proxinium (VB 4845), BC 819 (BioCancco Therapeutics, limiotic Therapeutics, limiotic Therapeutics) LOR 2040 (Lorus Therapeutics), urocanic acid, OGX 427 (OncoGenex) and SCH 721015 (Schering-Plow). Drug treatment can be coupled with conventional radiation or surgical therapy focused on cancerous tissue.
In one embodiment, the devices described in this document are loaded with an anesthetic agent, analgesic agent and combinations thereof. The anesthetic agent can be an aminoamide, an aminoester or combinations thereof. Representative examples of amide or aminoamide class anesthetics include articaine, bupivacaine, carticaine, dibucaine, etidocaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, ropivacaine and trimecain. Representative examples of ester-class anesthetics or aminoesters include amylocaine, benzocaine, butacaine, chloroprocaine, cocaine, cyclomethacin, dimetocaine, hexylcaine, larocaine, meprilcaine, metabutoxicaine, orthocaine, piperocaine, procaine, proparacaine, propoxycaine, proxycaine, tetraquinone, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine, proxycaine. Such anesthetics are typically weak bases and can be formulated as a salt, such as a hydrochloride salt, to make them soluble in water, although anesthetics can still be used in hydrate or free base form. Other anesthetics, such as lontocaine, can still be used. The drug can still be an antimuscarinic compound that exhibits an anesthetic effect, such as oxybutynin or propiverine. The drug may also include other drugs described herein, individually or in combination with a local anesthetic agent.
In certain embodiments, the analgesic agent includes an opiate. Representative examples of opioid agonists include alfentanil, allyprodin, alphaprodin, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, tenocine, diampromide, diamorphine, dimorhidine, dihydrochemide, dihydrochemide, dihydrochemide, dioxafetil, dipipanone, eptazocin, etoheptazine, ethyl methyl thiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypetidine, isomethadone, ketobemidone, metformin, meofenacyl, mephonamidone, mephonamidone, mezzanine, mezzanine, mezzanine nalbuphine, narcein, nicomorphine, norlevorfanol, normethadone, nalorphine, normorfine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, fenadoxone, phenomorphine, phenazocine, phenoperidine, piminodine, propanamidine, propyridamine, pyriramine tilidine, tramadol, pharmaceutically acceptable salts of the same and mixtures thereof. Other drugs
39/49 opiates, such as mu, kappa, delta and nociception opioid receptor agonists, are contemplated.
Representative examples of other suitable analgesic agents include such agents as salicylic alcohol, phenazopyridine hydrochloride, acetaminophen, acetylsalicylic acid, fluphenisal, ibuprofen, indoprofen, indomethacin and naproxen.
In certain embodiments, the drug delivery device is used to treat inflammatory conditions such as interstitial cystitis, radiation cystitis, painful bladder syndrome, prostatitis, urethritis, post-surgical pain and kidney stones. Non-limiting examples of specific drugs for these conditions include lidocaine, glycosaminoglycans (e.g., chondroitin sulfate, sulodexide), sodium polysulfate pentosan (PPS), dimethyl sulfoxide (DMSO), oxybutynin, mitomycin C, heparin, flavoxate, ketorolac or combinations thereof. For kidney stones, the drug (s) can be selected to treat pain and / or to promote the dissolution of kidney stones.
Other non-limiting examples of drugs that can be used in the treatment of HF include nerve growth factor monoclonal antibody (MAB) antagonists, such as Tanezumab and alpha-2-delta calcium channel modulators, such as PD299685 or gabepentin. The evidence suggests that the bladder expresses nerve growth factor (NGF) in a localized manner, since NGF delivered exogenously to the bladder induces bladder hyperactivity and increases the excitability of dissociated bladder afferent neurons (Nature Rev Neurosci 2008; 9 : 453-66). Accordingly, it may be advantageous to deliver a MAB or other agent against NGF in a localized manner using the described delivery devices, significantly reducing the total dose required for therapeutic efficacy. The evidence further suggests that binding of the alpha-2-delta unit to voltage-sensitive calcium channels, such as with gabapentin, may be effective in the treatment of neuropathic pain diseases such as fibromyalgia and that there may be common mechanisms between HF and diseases neuropathic pain (See Tech Urol. 2001 Mar, 7 (1): 47 to 49). Accordingly, it may be advantageous to deliver an alpha-2-delta calcium channel modulator, such as PD-299685 or gabepentin, in a localized manner, using the described delivery devices, minimizing drug-related systemic toxicities in the treatment of HF.
Other intravesical cancer treatments include small molecules, such as Apaziquone, adriamycin, AD-32, doxorubicin, doxetaxel, epirubicin, gemcitabine, HTI-286 (hemiasterline analogue), idarubicin, γ-linolenic acid, mitozantrona, meglumine and thiotepa; large molecules, such as EGF-dextran, HPC-doxorubicin, IL-12, IFN-a2b, IFNY, o-lactalbumin, p53 adenovector, TNFo; combinations, such as Epirubicin + BCG, IFN + pharmarubicin, Doxorubicin + 5-FU (oral), BCG + IFN and Pertússis toxin + cystectomy;
40/49 activated cells, such as macrophages and T cells; intravesical infusion such as IL-2 and Doxorubicin; chemosensitizers, such as BCG + antipyrinolytics (paramethylbenzoic acid or aminocaproic acid) and Doxorubicin + verapimil; imaging / diagnostic agents, such as Hexylaminolevulinate, 5-aminolevulinic acid, lododexyuridine, HMFG1 Mab + Tc99m; and agents for the management of local toxicity, such as formalin (hemorrhagic cystitis).
In a particular embodiment, the drug delivery device is used in association with the placement of a ureteral stent, such as to treat pain, urinary urgency or urinary frequency that results from the placement of a ureteral stent. Non-limiting examples of specific drugs for such treatment include antimuscarinics, blockers, narcotics and phenazopyridine, among others.
The drug delivery device can be used, for example, to treat urgency, incontinence or urinary frequency, including urge incontinence and neurogenic incontinence, as well as trigonitis. Drugs that can be used include anticholinergic agents, antispasmodic agents, antimuscarinic agents, β2 agonists, alpha adrenergics, anticonvulsants, norepinephrine uptake inhibitors, serotonin uptake inhibitors, calcium channel blockers, potassium channel openers and muscle relaxants. Representative examples of drugs suitable for the treatment of incontinence include oxybutynin, S-oxybutytin, emepronium, verapamil, imipramine, flavoxate, atropine, propantheline, tolterodine, rociverin, clenbuterol, darifenacin, terodiline, triospine, hyposcyamine, propane, hyposamine, propane, hyposcyamine, propane, hyposamine, propane, hyposamine, propane, hyposamine. clidinium bromide, dicyclomine HCI, glycopyrrolate amino alcohol ester, ipratropium bromide, mepenzolate bromide, methopolopolamine bromide, scopolamine hydrobromide, iotrope bromide, fesoterodine fumarate, YM-46303 (Yamanouchi Co., Japan) Nippon Kayaku Co., Japan), inaperisone, NS-21 (Nippon Shinyaku Orion, Formenti, Japan / ltalia), NC-1800 (Nippon Chemiphar Co., Japan), ZD-6169 (Zeneca Co., United Kingdom) and iodide of stylonium.
In yet another embodiment, the present intravesical drug delivery device is used to treat infections involving the bladder, prostate and urethra. Antibiotic, antibacterial, antifungal, antiprotozoal, antiseptic, antiviral and other anti-infectious agents can be administered to treat such infections. Representative examples of drugs for the treatment of infections include mitomycin, ciprofloxacin, norfloxacin, ofloxacin, methenamine, nitrofurantoin, ampicillin, amoxicillin, naphthylin, trimethoprim, trimethoprim sulfamethoxazine, methacrine, methaxylines, methazine, methazolines, methazine, methazine, methazine, methazine, methazine, methazine .
41/49
In other embodiments, the drug delivery device is used to treat fibrosis at a genitourinary site, such as the bladder or uterus. Representative examples of drugs for the treatment of fibroids include pentoxifylline (xanthine analog), antiTNF, antiTGF agents, GnRH analogs, exogenous progestants, antiprogestants, selective estrogen receptor modulators, danazol and NSAIDs.
The implantable drug delivery device can still be used to treat a flabby or spastic neurogenic bladder. Representative examples of drugs for the treatment of neurogenic bladder include analgesics or anesthetics, such as lidocaine, bupivacaine, mepivacaine, prilocaine, articaine and ropivacaine; anticholinergics; antimuscarinics such as oxybutynin or propiverine; a vaniloid, such as capsaicin or resiniferatoxin; antimuscarinics such as those that act on the muscarinic acetylcholine M3 receptor (mAChRs); antispasmodics that include GABAB agonists such as baclofen; botulinum toxins; capsaicins; alpha-adrenergic antagonists; anticonvulsants; serotonin uptake inhibitors such as amitriptyline; and nerve growth factor antagonists. In several modalities, the drug can be one that acts on bladder afferents or one that acts on cholinergic efferent transmission, as described in Reitz et al., Spinal Cord 42: 267 to 72 (2004).
In one embodiment, the drug is selected from those known for the treatment of incontinence due to hyperactivity of neurological detrusor and / or detrusor of low compatibility. Examples of these types of drugs include bladder relaxing drugs (for example, oxybutynin (an antimuscarinic agent with pronounced muscle relaxant activity and local anesthetic activity), propiverine, unsaturated, tiotropium, triospine, terodilin, tolterodine, propantelin, oxyphencycline and flavoxate and flavoxate tricyclic antidepressants); drugs for blocking nerves that innervate the bladder and urethra (for example, vaniloides (capsaicin, resiniferatoxin), botulinum toxin A); or drugs that modulate detrusor contraction force, urination reflex, detrusor-sphincter dyssynergy (eg, GABAb agonists (baclofen), benzodiazapines). In another embodiment, the drug is selected from those known to treat incontinence due to neurological sphincter deficiency. Examples of such drugs include alpha-adrenergic agonists, estrogens, beta-adrenergic agonists, tricyclic antidepressants (imipramine, amitriptyline). In yet another modality, the drug is selected from those known to facilitate bladder emptying (for example, alpha-adrenergic antagonists (phentolamine) or cholinergics). In yet another embodiment, the drug is selected from anticholinergic drugs (eg, dicyclomine), calcium channel blockers (eg, verapamil), tropane alkaloids (eg, atropine, scopolamine), nociceptin / orphanage CF and bethanechol (eg , muscarinic agonist m3, choline ester).
42/49
IV. Other Device Functions
The devices described in this document may include a radiopaque structure or portion to facilitate detection or vision (for example, through X-ray imaging or fluoroscopy) of the device by a physician as part of the recovery or implantation procedure. In one embodiment, the housing is constructed of a material that includes a radiopaque filler material, such as barium sulfate or other radiopaque material known in the art. Some housings can be made radiopaque by mixing radiopaque fillers, such as barium sulfate or other suitable material, during the processing of the material from which the housing is formed. The radiopaque material can be associated with the retaining frame in those embodiments that include a retaining frame. Ultrasound imaging or fluoroscopy can be used for imaging the device in vivo.
The implantable drug delivery device housing may additionally include a retrieval function, such as a cord, loop or other structure that facilitates removal of the device from the body cavity, for example, for removal of a non-resorbable device body following the release of the drug formulation from the solid drug units. In one case, the device can be removed from the bladder by engaging the cord to pull the device through the urethra. The device can be configured to assume a linear or relatively narrow shape when pulling the device through the recovery function in the lumen of a catheter or cystoscope or in the urethra.
V. Device Creation Methods
One embodiment of a method of creating an implantable drug delivery device may include forming a housing, forming several solid drug units, loading the solid drug units into the housing and, if necessary, associating the housing with a retaining frame. In some embodiments, the retaining frame, if present, can be associated with the housing before loading the solid drug units into the housing.
In some embodiments, the formation of the housings includes forming a flexible body that has walls that define one or more drug reservoir lumens and, optionally, a retaining frame lumen. For example, the housing can be formed by extruding or molding a polymer, such as silicone. In particular, the formation of the housing can include integrally forming two tubes or walls which are aligned and substantially joined along a longitudinal edge. Alternatively, the two lumens can be formed and attached separately to each other, such as with an adhesive. For modalities that do not include a retention frame, the housing can be programmed to assume the retention format. THE
43/49 programming may include heat treatment or crosslinking a portion of the material from which the housing is formed. Other methods of forming the housing and transmitting the retention format, if necessary, can still be employed.
The formation of a retaining frame may include forming a strip or elastic yarn from, for example, a superelastic alloy or shaped memory material and "programming" the elastic strip or yarn to naturally assume a retention shape. Heat treatment can be used to program the strip or elastic thread to assume a retention shape. For example, the holding frame may be formed by forming the strap or elastic wire into a pretzel shape and treating it with heat-band or elastic yarn at a temperature higher than 500 ^Q C for a period of more than five minutes. In embodiments where the retaining frame comprises a low modulus elastomer, the step of forming the retaining frame may comprise the formation of one or more windings, coils, loops or spirals in the frame so that the retaining frame functions as a spring. For example, the retaining frame can be formed through extrusion, liquid injection molding, transfer molding or insertion molding, among others.
The association of the housing with a retaining frame may comprise the insertion of a retaining frame into a lumen of the retaining frame, if present, associated with the housing. The distal end of the retaining frame can be blunt to facilitate guiding the retaining frame through the lumen of the retaining frame without puncturing the housing wall. The association of the housing with the retaining frame may additionally include filling in a lumen of the retaining frame, when present, with a filling material after the retaining frame is loaded. The filling material can occupy a portion or all of the rest of the retaining frame lumen not occupied by the retaining frame. The association of the housing with the retaining frame portion may comprise integrally forming the two portions together, such as over-molding the housing and surrounding the retaining frame.
Modular housing or monolithic housing units can be made through an extrusion or molding process. The extruded or molded structures can be further processed in the complete housing by one or more of cutting, perforating or mechanical punching to form the individual drug reservoir lumens and / or modular housing unit. Alternatively, the drug reservoir lumens or through holes can be molded into the structure. The components can still be assembled or connected together with adhesives, fasteners and / or tied together with the retaining frame.
44/49
The solid drug units can be loaded onto the drug delivery device by any suitable means, as described above with reference to Figures 11 to 22. Other methods of loading solid drug unit can be used.
Some steps or substeps of the method of creating an implantable drug delivery device can be performed in other orders or simultaneously. For example, the retaining frame can be associated with the housing before or after the drug units are loaded into the body of the device.
SAW. Drug Delivery Methods
The devices and methods disclosed in this document can be adapted for use in humans, men or women, adults or children, or for use in animals, such as for domestic or veterinary applications. Accordingly, the term "patient" can refer to a human or other mammalian subject.
The device can be implanted non-surgically and can deliver the drug for several days, weeks, months or more after the implantation procedure is complete. For example, the device can be positioned using a positioning instrument, such as a catheter or cytoscope, positioned in a natural body lumen, such as the urethra, in a body cavity, such as the bladder. The positioning instrument is typically removed from the body's lumen while the drug delivery device remains in the bladder or other body cavity for a prescribed treatment period.
The device, in some modalities, can be positioned on a patient's bladder in an independent procedure or together with another surgery or other urological procedure, before, during or after the other procedure. The device can deliver one or more drugs that are delivered to regional and / or local tissues for therapy or prophylaxis, perioperatively, postoperatively or both.
In one example, the device is implanted by passing the drug delivery device through a positioning instrument and releasing the device from the positioning instrument on the body. In cases where the device is positioned in a body cavity such as the bladder, the device takes on a retention shape, such as an upper or expanded profile shape, as the device emerges from the positioning instrument in the cavity. The positioning instrument can be any suitable lumen device, such as a catheter, for example, a urethral catheter or cytoscope. These terms are used interchangeably in this document, unless expressly stated otherwise. The positioning instrument can be a commercially available device or a device specially adapted for the present drug delivery devices.
45/49
The drug delivery device can be passed through the positioning instrument, driven by a stylus or flow of lubricant or other fluid, for example, until the drug delivery device leaves a lumen of the instrument as it passes through the bladder . Therefore, the device can be implanted in the bladder of a human male or female patient in need of treatment, adults or children.
Once positioned in vivo, the device can subsequently release one or more drug (s) for the treatment of one or more conditions, localized to one or more tissues at the positioning site and / or regionally to other distal tissues of the positioning site. The release can be controlled and can release the drug in an effective amount over an extended period. After that, the device can be removed, reabsorbed, excreted or some combination thereof. In certain embodiments, the device resides in the bladder releasing the drug for a predetermined period, such as two weeks, three weeks, four weeks, a month or more.
Once implanted, the device can provide periodic, extended, continuous or intermittent delivery of a desired amount of drug over a predetermined, desired period. In embodiments, the device can deliver the desired dose of drug over an extended period, such as 12 hours, 24 hours, 5 days, 7 days, 10 days, 14 days, or 20, 25, 30, 45, 60 or 90 days , or more. The rate of delivery and dosage of the drug can be selected depending on the drug being delivered and the disease or condition being treated.
In certain embodiments, drug elution from the device occurs following dissolution of the drug within the device. The body fluid enters the device, comes into contact with the drug and solubilizes the drug, and after that the dissolved drug diffuses from the device or flows from the device under osmotic pressure or through diffusion. For example, the drug can be solubilized in contact with urine in cases where the device is implanted in the bladder.
The device can be used to treat interstitial cystitis, radiation cystitis, pelvic pain, overactive bladder syndrome, bladder cancer, neurogenic bladder, non-neuropathic or neuropathic sphincter-bladder dysfunction, infection, post-surgical pain or other diseases, disorders and conditions treated with drugs delivered to the bladder. The device can deliver drug locally to the bladder and regionally to other sites close to the bladder. The device can deliver drugs that improve bladder function, such as bladder capacity, complacency and / or frequency of uninhibited contractions, that reduce pain and discomfort in the bladder or other neighboring areas, or that have other effects or combinations of themselves. The device positioned in the bladder can still deliver a therapeutically effective amount of one or more drugs to
46/49 other genitourinary sites within the body, such as other locations within the body's reproductive or urological systems, including the kidneys, urethra, ureters, penis, testicles, seminal vesicles, vas deferens, ejaculatory ducts, prostate, vagina, uterus, ovaries or fallopian tubes, among others or combinations thereof. For example, the drug delivery device can be used to treat kidney stones or fibrosis, erectile dysfunction, among other diseases, disorders and conditions.
In one embodiment, the drug delivery device is implanted in a bladder to deliver an anesthetic agent for pain management that arises from any source, such as a disease or disorder in genitourinary tissues, or pain resulting from any localization. bladder procedure, such as surgery, catheterization, ablation, implantation of a medical device, or removal of a foreign object or stone, among others. For example, an anesthetic agent can be released into the bladder for regional delivery to neighboring sites to manage nearby pain that arises from any source, such as post-operative pain associated with the passage of a medical device in or through a ureter or other postoperative pain in distant sites of the bladder.
In one embodiment, a device that has a charge of mitomycin C can be delivered to the bladder and mitomycin C can be released continuously from the device over an extended period. The drug load, in this modality, is in a solid form, to reduce the size of the device and, thus, to reduce bladder irritation and patient discomfort.
In one embodiment, the device can have two loads of drug that are released at different times. The first charge can be adapted for relatively quick release, while the second charge can be adapted for more continuous release.
Subsequently, the device can be recovered from the body, as in cases where the device is not absorbable or otherwise needs to be removed. Recovery devices for this purpose are known in the art or can be specially produced. The device can still be completely or partially bioerosible, resorbable or biodegradable, so that recovery is unnecessary, as the entire device is reabsorbed or the device degrades sufficiently to expel, for example, from the bladder during urination. The device cannot be recovered or reabsorbed until part of the drug, or preferably most or all of the drug, has been released. If necessary, a new drug loaded device can be substantially implanted, either during the same procedure as recovery or at a later time.
47/49
The present invention can be further understood with reference to the following non-limiting examples.
Example 1: Diffusion of Mitomycin C from Different Device Designs
A study was carried out to determine the feasibility of delivering mitomycin C (“MMC”), a drug with low aqueous solubility, from various housing structures. Eight devices in total - two devices of four different configurations - were formed from 2.65 mm ID silicone tubes (“600” tubing) and loaded with pressed MMC tablets for a total charge of approximately 60 mg .
The four configurations were (1) a device that has a single open end, featuring a single face of the MMC tablet, (2) a device that has two opposite open ends, featuring two faces of the MMC tablet, (3) a device which has two opposing open ends and a cut in the piping between the two MMC tablets, thereby effectively displaying four faces of the MMC tablets, and (4) and an uncontrolled MMC tablet (ie in the housing), exposing the entire outer surface of the tablet. Two of each configuration was tested.
Each of the four configurations was placed separately in 100 ml of 37 ° C deionized water. The first three drug / device configurations provided a constant surface area of the solid drug for contact with water during the test period. In contrast, with the fourth configuration - uncontrolled drug tablets - the surface area of solid drug exposed to water changed over time as the drug on the surface dissolved. The dissolution / release of the MMC was measured periodically by removing aliquots from the water and analyzing the MMC using HPLC directly after each time point.
The 7-day release rate was calculated. As shown in Figure 40, the release profile data demonstrated that it is feasible to deliver a drug through dissolution and diffusion from open areas in the silicon housing structures and that the release rate can be increased by increasing the surface of the solid form of the drug that is exposed to the fluid environment, for example, the aqueous solution, on which the drug loaded device is positioned.
Figure 41 shows the chromatograms for each of days 0 to 8 for configuration 3. The relatively constant level of MMC can be observed. Related compounds (RRT 0.632 and RT 0.836) are believed to be degradation products of MMC. It is observed, however, that the degradation products do not increase over time, which suggests that the degradation of MMC does not occur while housed in the device, but primarily or entirely after dissolution and release.
Example 2: In vitro release of Mitomycin C from the Housing Module
48/49
The housing device modules loaded with mitomycin C (MMC) tablets were created and an in vitro release of MMC was observed.
The tablets were created using Carver Press from 100% mitomycin C powder. The diameter of the tablets was 2.1 mm or 2.6 mm with a height of 2 mm. The mass of the tablet was approximately 10 mg for a 2.1 mm diameter tablet and 16 mg for a 2.6 mm diameter tablet. The MMC 402 tablet is shown in Figure 42a.
The housing modules were created from silicone tube segments of silicone adhesive. Figure 42b shows an assembled device module 400, in which the MMC tablet 402 is shown loaded inside the housing module 404. The surface 'b' of the tablet 402 was surrounded by the silicone tube 406 and the surface 'c' was in contact with silicone adhesive 408.
The ‘a’ surface of the MMC 402 Tablet was exposed to a deionized water release medium for an 8-day trial period. Specifically, housing module 400 was submerged in 20 ml of deionized water at 37 ° C, with the release medium being replenished entirely daily during the test period. Cumulative MMC release was measured over the test period. The in vitro release data are shown in Figure 43 (n = 3; the error bars indicate SD around the mean.) (Some error bars are not shown, that is, when they are smaller than the symbols.) .
It was observed that the erosion surface spread from the ‘a’ surface to the ‘c’ surface and the close to zero order release was achieved until the tablet was completely eroded. In ‘A’, three modules were used while one was used in ‘C’. The data shows that the release rate was determined by the total exposed area, or by the 'a' surface in Figure 42b.
Example 3: In vitro release of Mitomycin C from the Housing Module
The experiment described in Example 2 was repeated with modifications to the MMC tablet formulation, to observe the effect of including excipients. The same setup and method of the experiment as ‘C’ in Figure 43 was used. 2.1 mm diameter tablets with a height of 2 mm were created by adding 5% (w / w) PVP (Plasdone K29 / 32), PEC 100K, or PEG 8K to 95% mitomycin C powder and then pressing the mixture to form tablets, each having a mass of approximately 10 mg. As shown in Figure 44, an increased release rate was observed with the addition of these excipients (n = 3; the error bars indicate SD around the mean) (Some error bars are not shown, that is, when they are smaller than the symbols.).
The publications cited in this document and the materials for which they are cited are specifically incorporated by reference. Modifications
49/49 and variations of the methods and devices described in this document will be obvious to those skilled in the art from the previous detailed description. Such modifications and variations are intended to fall within the scope of the attached claims.

权利要求:
Claims (26)
[1]
1. Implantable drug delivery device, characterized by the fact that it comprises:
a drug housing portion that comprises at least one solid drug unit that comprises a drug, and at least one housing that encloses a first portion of the surface of at least one solid drug unit and that has at least one defined opening that exposes a second portion of the surface of at least one solid drug unit, wherein the device is elastically deformable between a relatively rectified shape suitable for insertion through a lumen into a patient's body cavity and a retention shape suitable for retaining the device within the body cavity, and where the release of drug from the device is controlled by erosion of the second exposed portion of the surface of at least one solid drug unit.
[2]
2. Device according to claim 1, characterized by the fact that the release of the drug from the device is controlled by erosion of the second exposed portion of the surface of at least one solid drug unit, such that an area of the total exposed surface of at least one solid drug unit remains substantially constant throughout or a substantial portion of the drug release period which can beneficially provide a relatively constant rate of drug release and the rate of drug release is directly proportional a and limited by the total exposed surface area.
[3]
Device according to claim 1 or 2, characterized in that the at least one solid drug unit is a tablet comprising a low solubility drug.
[4]
Device according to any one of claims 1 to 3, characterized in that the rate of drug release from the drug delivery device is zero order for at least 24 hours.
[5]
5. Drug delivery device according to claim 1, characterized by the fact that:
the drug housing portion comprises at least two solid drug units, and the at least one housing has at least two defined openings that expose a second portion of the surface of each solid drug unit.
[6]
6. Drug delivery device according to claim 5, characterized in that the at least one housing comprises at least three openings
2/4 defined so that a third portion of the surface of at least one unit of solid drug is exposed.
[7]
Drug delivery device according to claim 5, characterized in that the at least one housing comprises at least four defined openings so that a third portion of the surface of each solid drug unit is exposed.
[8]
Drug delivery device according to claim 5, characterized in that the at least one housing is configured to expose a constant surface area of at least two solid drug units in at least two openings defined according to at least two units of solid drug are dissolved in the exposed surface area.
[9]
Drug delivery device according to claim 5, characterized in that the at least one housing comprises a flexible elongated monolithic structure that has a longitudinal geometric axis and a plurality of substantially oriented separate drug reservoir lumens perpendicular to the longitudinal geometric axis.
[10]
Drug delivery device according to claim 9, characterized in that the at least one housing additionally comprises a retaining frame lining substantially parallel to the longitudinal geometric axis and a retaining frame disposed in the frame lining retention.
[11]
Drug delivery device according to claim 5, characterized in that the at least one housing comprises one or more modular housing units.
[12]
Drug delivery device according to claim 11, characterized by the fact that the one or more modular housing units comprises (m):
(i) a drug reservoir luren that houses at least one of the solid drug units, and (ii) at least one retention frame luren, the plurality of modular housing units having a shared retention frame that extends through the retaining frame lumens.
[13]
Drug delivery device according to claim 12, characterized in that the drug reservoir lumen has two opposite openings that expose the correspondingly opposite end surfaces of at least one solid drug unit housed therein.
3/4
[14]
Drug delivery device according to claim 12, characterized in that the drug reservoir lumen is oriented substantially parallel to the retention frame lumen.
[15]
Drug delivery device according to claim 12, characterized in that the drug reservoir lumen is oriented substantially perpendicular to the retention frame lumen.
[16]
Drug delivery device according to any one of claims 5 to 15, characterized in that the solid drug unit is a tablet comprising a low solubility drug.
[17]
17. Drug delivery device insertable into a patient's bladder, characterized by the fact that it comprises:
a retaining frame comprising an elastic thread having a wound shape;
a plurality of solid drug tablets, each having a peripheral surface between opposite end faces;
a plurality of modular housing units attached to the retaining frame and holding the plurality of solid drug tablets, wherein each modular housing unit holds one of the solid drug tablets around its peripheral surface and has one or two openings that expose, respectively, one or both end faces of each solid drug tablet.
[18]
18. Drug delivery device according to claim 17, characterized in that the elastic thread is elastically deformable between a relatively rectified shape suitable for insertion through the patient's urethra into the patient's bladder and the suitable coiled shape for retain the device inside the bladder.
[19]
19. Drug delivery device according to claim 17 or 18, characterized in that each modular housing unit has two openings to expose both end faces of each solid drug tablet.
[20]
20. Drug delivery device according to any one of claims 17 to 19, characterized by the fact that each of the solid drug tablets is retained in its modular housing unit by friction coupling, adhesive, tongues or other resource mechanical lock or a combination thereof, contacting the peripheral surface of the solid drug unit.
[21]
21. Drug delivery device insertable into a patient's bladder, characterized by the fact that it comprises:
4/4 a housing comprising a flexible elongated monolithic structure having a longitudinal geometric axis and a plurality of separate drug reservoir lumens oriented substantially and perpendicular to the longitudinal geometric axis; and a plurality of solid drug tablets arranged in the plurality of separate drug reservoir lumens.
[22]
22. Drug delivery device according to claim 21, characterized in that each separate drug reservoir lumen holds one of the solid drug tablets around its peripheral surface and said drug reservoir lumen has a or two openings which expose, respectively, one or both end faces on opposite sides of the peripheral surface of said drug tablet.
[23]
23. Drug delivery device according to claim 21 or 22, characterized in that it additionally comprises a retaining frame.
[24]
24. Drug delivery device according to any of claims 21 to 23, characterized in that each of the solid drug tablets is retained in its drug reservoir lumen by friction coupling, adhesive, tongues or other mechanical locking feature or a combination thereof, contacting the peripheral surface of the solid drug tablet.
[25]
25. Drug delivery device according to any one of claims 17 to 24, characterized in that the solid drug tablets comprise a low solubility drug.
[26]
26. Drug delivery device according to any one of claims 1 to 25, characterized in that the drug comprises gemcitabine, docetaxel, carboplatin, cisplatin, tropium, tolterodine, mitomycin C or a combination thereof.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2019202670B2|2020-04-02|Drug delivery devices with drug-permeable component and methods

---

US9107816B2|2015-08-18|Implantable device for controlled dissolution and diffusion of low solubility drug

---

US20170095651A1|2017-04-06|Ureteral stent drug delivery device, kit, and method

---

JP5945544B2|2016-07-05|Time-selective bioabsorbable or disintegratable drug delivery system and method

---

US20210121670A1|2021-04-29|Drug Delivery Devices with Drug-Permeable Component and Methods

---

US20210146013A1|2021-05-20|Drug delivery devices and methods

同族专利:

---

公开号 | 公开日

---

RU2013138621A|2015-03-10|

---

RU2598057C2|2016-09-20|

---

IL227530A|2016-02-29|

---

JP2014509315A|2014-04-17|

---

CN103379902A|2013-10-30|

---

US20120203203A1|2012-08-09|

---

EP2670398A1|2013-12-11|

---

CN103379902B|2015-11-25|

---

EP2670398B1|2017-06-07|

---

JP6043730B2|2016-12-14|

---

AU2012211960B2|2016-12-01|

---

IL227530D0|2013-09-30|

---

WO2012106714A1|2012-08-09|

---

KR20140048086A|2014-04-23|

---

ES2637388T3|2017-10-13|

---

US9107816B2|2015-08-18|

---

CA2825399A1|2012-08-09|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3854480A|1969-04-01|1974-12-17|Alza Corp|Drug-delivery system|

---

US4016251A|1972-08-17|1977-04-05|Alza Corporation|Vaginal drug dispensing device|

---

US3888975A|1972-12-27|1975-06-10|Alza Corp|Erodible intrauterine device|

---

US3901232A|1973-10-26|1975-08-26|Alza Corp|Integrated device for administering beneficial drug at programmed rate|

---

US3935860A|1974-08-21|1976-02-03|Alza Corporation|Intrauterine device with restrictor for maintaining device in uterine cavity|

---

US4235236A|1979-02-12|1980-11-25|Alza Corporation|Device for dispensing drug by combined diffusional and osmotic operations|

---

US4392848A|1979-06-25|1983-07-12|The Procter & Gamble Company|Catheterization|

---

GB2079158B|1980-06-09|1985-01-09|Ahi Operations Ltd|Intra-vaginal devices|

---

US4475916A|1982-03-18|1984-10-09|Merck & Co., Inc.|Osmotic drug delivery system|

---

US4629449A|1982-07-29|1986-12-16|Alza Corporation|Vaginal dispenser for dispensing beneficial hormone|

---

US5366738A|1982-07-29|1994-11-22|Merck & Co., Inc.|Controlled release drug dispersion delivery device|

---

US4655219A|1983-07-22|1987-04-07|American Hospital Supply Corporation|Multicomponent flexible grasping device|

---

DE3332156A1|1983-09-06|1985-03-21|Peter 6000 Frankfurt Prezelj|Nose clip|

---

NZ207341A|1984-03-01|1988-02-29|Harvey Alex Ind Ltd|Device containing chemical impregnants for insertion into a body cavity of an animal|

---

US4968507A|1984-06-20|1990-11-06|Merck & Co., Inc.|Controlled porosity osmotic pump|

---

US4871542A|1987-04-30|1989-10-03|Ferring Service Center, N.V.|Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract|

---

US5545208A|1990-02-28|1996-08-13|Medtronic, Inc.|Intralumenal drug eluting prosthesis|

---

WO1993006792A1|1991-10-04|1993-04-15|Scimed Life Systems, Inc.|Biodegradable drug delivery vascular stent|

---

ZA927779B|1991-10-10|1993-07-05|Alza Corp|Osmotic drug delivery devices with hydrophobic wall materials.|

---

US5441550A|1992-03-26|1995-08-15|The University Of Tennessee Research Corporation|Post-treatment of laminated nonwoven cellulosic fiber webs|

---

US5499997A|1992-04-10|1996-03-19|Sharpe Endosurgical Corporation|Endoscopic tenaculum surgical instrument|

---

ES2150427T3|1992-06-02|2000-12-01|Bard Inc C R|PROCEDURE AND DEVICE OF IMPLANT FOR THE SUPPLY OF LONG-TERM DRUGS.|

---

US5523092A|1993-04-14|1996-06-04|Emory University|Device for local drug delivery and methods for using the same|

---

US5516522A|1994-03-14|1996-05-14|Board Of Supervisors Of Louisiana State University|Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same|

---

IL116433A|1994-12-19|2002-02-10|Galen Chemicals Ltd|INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS|

---

GB9522403D0|1995-11-01|1996-01-03|Hoechst Roussel Ltd|Intravaginal drug delivery device|

---

US6171298B1|1996-05-03|2001-01-09|Situs Corporation|Intravesical infuser|

---

US6183461B1|1998-03-11|2001-02-06|Situs Corporation|Method for delivering a medication|

---

US5869081A|1996-06-28|1999-02-09|The Population Council|Progesterone vaginal ring for treatment of infertility|

---

US5797898A|1996-07-02|1998-08-25|Massachusetts Institute Of Technology|Microchip drug delivery devices|

---

US5972372A|1996-07-31|1999-10-26|The Population Council, Inc.|Intravaginal rings with insertable drug-containing core|

---

US6464999B1|1998-06-17|2002-10-15|Galt Incorporated|Bioadhesive medical devices|

---

US5756127A|1996-10-29|1998-05-26|Wright Medical Technology, Inc.|Implantable bioresorbable string of calcium sulfate beads|

---

US6749617B1|1997-11-04|2004-06-15|Scimed Life Systems, Inc.|Catheter and implants for the delivery of therapeutic agents to tissues|

---

US5830230A|1997-03-07|1998-11-03|Micro Therapeutics, Inc.|Method of intracranial vascular embolotherapy using self anchoring coils|

---

GB2338414B|1997-04-03|2001-12-19|Point Biomedical Corp|Intravesical drug delivery system|

---

TW358031B|1997-04-11|1999-05-11|Akze Nobel N V|Drug delivery system for 2 or more active substances|

---

JP2001524124A|1997-05-07|2001-11-27|ガレン（ケミカルズ）リミティド|Vaginal drug delivery device for administration of testosterone and testosterone precursor|

---

WO1998053758A1|1997-05-28|1998-12-03|Dec International Nz Limited|Intra-vaginal device for pigs|

---

US6197327B1|1997-06-11|2001-03-06|Umd, Inc.|Device and method for treatment of dysmenorrhea|

---

US6039968A|1997-06-24|2000-03-21|Hoechst Marion Roussel|Intravaginal drug delivery device|

---

DE69724942D1|1997-07-04|2003-10-23|Thomson Tubes & Displays|Color picture tube with an in-line electron gun|

---

US6267761B1|1997-09-09|2001-07-31|Sherwood Services Ag|Apparatus and method for sealing and cutting tissue|

---

US6482837B1|1998-04-24|2002-11-19|University Of Rochester|Antimuscarinic compounds and methods for treatment of bladder diseases|

---

US20050238733A1|2000-01-05|2005-10-27|Richard Henry|Topical anesthesia of the urinary bladder|

---

US6293923B1|1999-03-15|2001-09-25|Innoventions, Inc.|Intravesicular balloon|

---

US6083933A|1999-04-19|2000-07-04|Stellar International Inc.|Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution|

---

US6139535A|1999-05-27|2000-10-31|Situs Corporation|Method and apparatus for placement and activation of a medical device within a body cavity|

---

US6413540B1|1999-10-21|2002-07-02|Alcon Universal Ltd.|Drug delivery device|

---

DE60041825D1|1999-11-17|2009-04-30|Boston Scient Ltd|MINIATURIZED DEVICES FOR DISPENSING MOLECULES IN A CARRIER FLUID|

---

CA2393603C|1999-12-10|2010-09-21|Massachusetts Institute Of Technology|Microchip devices for delivery of molecules and methods of fabrication thereof|

---

US6753011B2|2000-01-14|2004-06-22|Osmotica Corp|Combined diffusion/osmotic pumping drug delivery system|

---

US6988983B2|2000-04-14|2006-01-24|Solace Therapeutics, Inc.|Implantable self-inflating attenuation device|

---

US6682473B1|2000-04-14|2004-01-27|Solace Therapeutics, Inc.|Devices and methods for attenuation of pressure waves in the body|

---

US6398718B1|2000-06-15|2002-06-04|Innoventions, Inc.|Intravesicular device|

---

AU2001286726B2|2000-08-24|2007-03-22|Sidney Lerner|Non-hormonal vaginal contraceptive|

---

DE50107522D1|2000-12-22|2006-02-02|Henkel Kgaa|METHOD FOR PRODUCING A PACKAGING FILLED WITH TABLETS|

---

AU2002241834B2|2001-01-09|2006-11-09|Microchips, Inc.|Flexible microchip devices for opthalmic and other applications|

---

CA2442281C|2001-03-27|2010-06-08|Galen Limited|Intravaginal drug delivery devices for the administration of an antimicrobial agent|

---

US7438701B2|2001-07-26|2008-10-21|Durect Corporation|Local concentration management system|

---

US20030118649A1|2001-10-04|2003-06-26|Jinming Gao|Drug delivery devices and methods|

---

US7722894B2|2001-10-22|2010-05-25|Massachusetts Institute Of Technology|Biodegradable polymer|

---

US7005138B2|2001-12-21|2006-02-28|Duramed Pharmaceuticals, Inc.|Method of systematically delivering SSRIs|

---

US7473273B2|2002-01-22|2009-01-06|Medtronic Vascular, Inc.|Stent assembly with therapeutic agent exterior banding|

---

GB2385273B|2002-02-13|2004-05-26|Deborah Huang|Drug delivery device|

---

US6899890B2|2002-03-20|2005-05-31|Kv Pharmaceutical Company|Bioadhesive drug delivery system|

---

US8685427B2|2002-07-31|2014-04-01|Boston Scientific Scimed, Inc.|Controlled drug delivery|

---

DE10247689A1|2002-10-12|2004-04-22|Martin Rahe|Urinary bladder implants for prolonged prevention and treatment of urinary tract infections, comprising antimicrobial active agent, preferably silver, incorporated in carrier, preferably of shape memory material|

---

US7504387B2|2002-10-16|2009-03-17|Arthrodynamic Technologies, Animal Health Division, Inc.|Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis|

---

US20040260272A1|2002-10-22|2004-12-23|Friedman Craig D.|Method and system for intravesicular delivery of therapeutic agents|

---

DE60324194D1|2002-12-23|2008-11-27|Medtronic Inc|CATHETER WITH SEVERAL INFUSION SECTIONS AND RELATED METHODS|

---

AU2005209322B2|2004-01-28|2011-05-19|The Regents Of The University Of California|Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis|

---

US20050234431A1|2004-02-10|2005-10-20|Williams Michael S|Intravascular delivery system for therapeutic agents|

---

US7647112B2|2004-02-11|2010-01-12|Ethicon, Inc.|System and method for selectively stimulating different body parts|

---

US8353896B2|2004-04-19|2013-01-15|The Invention Science Fund I, Llc|Controllable release nasal system|

---

WO2005115245A1|2004-05-28|2005-12-08|Dynaventions Inc.|Intravesicular device|

---

EP2215996B1|2004-12-16|2013-04-03|Iscience Interventional Corporation|Ophthalmic implant for treatment of glaucoma|

---

US20060134176A1|2004-12-22|2006-06-22|Bausch & Lomb Incorporated|Pharmaceutical delivery system and method of use|

---

US7862552B2|2005-05-09|2011-01-04|Boston Scientific Scimed, Inc.|Medical devices for treating urological and uterine conditions|

---

CA2618349C|2005-08-11|2016-05-31|Massachusetts Institute Of Technology|Intravesical drug delivery device and method|

---

NL1030608C2|2005-12-06|2007-06-07|Patrick Antonius Hendri Meeren|Blister package, assembly of a blister package and a holder, and method for packaging objects.|

---

US20070172507A1|2006-01-26|2007-07-26|Paul Zupkas|Transluminal drug delivery methods and devices|

---

US20070172508A1|2006-01-26|2007-07-26|Paul Zupkas|Transluminal drug delivery methods and devices|

---

WO2007109247A2|2006-03-20|2007-09-27|Duramed Pharmaceuticals, Inc.|Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same|

---

EP3449873A1|2006-03-31|2019-03-06|Mati Therapeutics Inc.|Drug delivery structures and compositions for nasolacrimal system|

---

US7824383B2|2006-06-16|2010-11-02|Family Health International|Vaginal drug delivery system and method|

---

US8187255B2|2007-02-02|2012-05-29|Boston Scientific Scimed, Inc.|Medical devices having nanoporous coatings for controlled therapeutic agent delivery|

---

WO2009029958A2|2007-08-30|2009-03-05|Sunstorm Research Corporation|Implantable delivery device|

---

WO2009029744A1|2007-08-31|2009-03-05|Wilson-Cook Medical, Inc.|Medical implant having improved drug eluting features|

---

PL2231254T3|2007-12-11|2014-10-31|Massachusetts Inst Technology|Implantable drug delivery device|

---

US8521273B2|2008-01-29|2013-08-27|Gilbert H. KLIMAN|Drug delivery devices, kits and methods therefor|

---

WO2010019507A2|2008-08-09|2010-02-18|Massachusetts Institute Of Technology|Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues|

---

US7772872B2|2008-09-08|2010-08-10|Altera Corporation|Multi-row block supporting row level redundancy in a PLD|

---

RU2393886C2|2008-09-30|2010-07-10|Георгий Цыренович Дамбаев|Device for treating somatic diseases|

---

US9017312B2|2009-09-10|2015-04-28|Taris Biomedical Llc|Implantable device for controlled drug delivery|

---

BRPI1014320B1|2009-06-26|2020-04-14|Liris Biomedical Inc|drug dosage form, and implantable drug dispensing device|

---

US8721621B2|2009-09-10|2014-05-13|Taris Biomedical, Inc.|Systems and methods for deploying devices to genitourinary sites|

---

US8167836B2|2009-12-08|2012-05-01|Taris Biomedical, Inc.|Tissue expander configured for drug delivery|

---

PT2512581T|2009-12-17|2021-04-27|Taris Biomedical Inc|Implantable device with intravesical tolerability and methods of treatment|

---

US20110218488A1|2010-03-05|2011-09-08|Taris Biomedical, Inc.|Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites|

---

HUE052160T2|2010-08-05|2021-04-28|Taris Biomedical Llc|Ureteral stent drug delivery device and kit|

---

ES2822118T3|2010-08-05|2021-04-29|Taris Biomedical Llc|Implantable Drug Delivery Devices for Genitourinary Sites|

---

WO2012048114A1|2010-10-06|2012-04-12|Taris Biomedical, Inc.|Time-selective bioresorbable or collapsible drug delivery systems and methods|

---

US9457176B2|2010-10-06|2016-10-04|Taris Biomedical Llc|Implantable drug delivery device with bladder retention feature|DK170754B1|1992-03-12|1996-01-08|Damixa As|Single lever mixer|

---

RU2761981C2|2012-05-19|2021-12-14|ТАРИС Биомедикал ЛЛК|Implantable urological device with improved extraction characteristic|

---

CN104640549B|2012-08-31|2018-09-07|塔里斯生物医药公司|Drug delivery system for treating carcinoma of urinary bladder and method|

---

MX367070B|2012-08-31|2019-08-05|Taris Biomedical Llc|Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine.|

---

RU2670749C9|2012-09-18|2018-12-13|ТАРИС Биомедикал ЛЛК|Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium|

---

EP2964310A1|2013-03-05|2016-01-13|TARIS Biomedical LLC|Drug delivery devices and methods for controlled drug release through device orifice|

---

BR112015022433A2|2013-03-15|2017-07-18|Taris Biomedical Llc|drug permeable drug delivery devices and methods|

---

WO2014144066A1|2013-03-15|2014-09-18|Taris Biomedical, Inc|Drug delivery devices and methods for drug delivery|

---

AU2014309012B2|2013-08-19|2019-03-14|Taris Biomedical Llc|Multi-unit drug delivery devices and methods|

---

MX2016011333A|2014-03-06|2016-12-07|Taris Biomedical Llc|Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.|

---

AU2015259361B2|2014-05-12|2020-11-05|Taris Biomedical Llc|Drug delivery devices and methods|

---

US10413507B2|2014-06-11|2019-09-17|Massachusetts Institute Of Technology|Enteric elastomers|

---

US20170266112A1|2014-06-11|2017-09-21|Massachusetts Institute Of Technology|Residence structures and related methods|

---

DK3160442T3|2014-06-26|2019-06-11|Taris Biomedical Llc|Devices and methods for intravesical drug delivery comprising drug polymer matrix systems|

---

KR20170045223A|2014-08-19|2017-04-26|더 리젠츠 오브 더 유니버시티 오브 캘리포니아|Implants for localized drug delivery and methods of use thereof|

---

CA2962004A1|2014-09-24|2016-03-31|Wellesley Pharmaceuticals, Llc|Pharmaceutical formulation for reducing bladder spasms and method of use thereof|

---

ES2734394T3|2015-03-30|2019-12-05|Taris Biomedical Llc|Devices for local administration of drugs to the upper urinary tract|

---

EP3285850A1|2015-04-23|2018-02-28|TARIS Biomedical LLC|Drug delivery devices with drug-permeable component and methods|

---

WO2017132372A1|2016-01-26|2017-08-03|Taris Biomedical Llc|Multi-lumen drug delivery devices|

---

WO2017151983A1|2016-03-02|2017-09-08|Taris Biomedical Llc|Osmotic drug delivery devices and methods of making osmotic drug delivery devices|

---

RU2764747C2|2016-05-06|2022-01-20|ТЭРИС БАЙОМЕДИКАЛ ЭлЭлСи|Method for treatment of cancer of lower pathway urothelium|

---

RU175247U1|2016-11-24|2017-11-28|Андрей Борисович Бондарев|Intraventricular stent to reduce weight or lose weight|

---

LT3432970T|2017-02-01|2021-05-10|Taris Biomedical Llc|In vivo drug delivery devices|

---

EP3658153A4|2017-07-25|2021-04-21|TARIS Biomedical LLC|Methods of treating tumor metastasis|

---

CA3081839A1|2017-11-08|2019-05-16|Taris Biomedical Llc|Methods of treatment and maintenance therapy for bladder cancer using gemcitabine|

---

US11173291B2|2020-03-20|2021-11-16|The Regents Of The University Of California|Implantable drug delivery devices for localized drug delivery|

法律状态:
2019-10-01| B08F| Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]|

---

2019-11-26| B25D| Requested change of name of applicant approved|Owner name: LIRIS BIOMEDICAL, INC. (US) |

---

2019-12-17| B25A| Requested transfer of rights approved|Owner name: TARIS BIOMEDICAL LLC (US) |

---

2020-01-21| B08K| Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]|Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161439665P| true| 2011-02-04|2011-02-04|

---

PCT/US2012/023989|WO2012106714A1|2011-02-04|2012-02-06|Implantable device for controlled release of low solubility drug|

---